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The vast majority of common disease-associated genetic variation is non-coding. However, 
the route by which non-coding genetic variation influences disease susceptibility is largely 
unknown. The dissection of the genetic control of variation in intermediate phenotypes, 
such as protein abundance or DNA methylation status, represents an important method to 
interrogate the pathway between genotype and phenotype. 
 
Using array-based technologies, I assessed the genetic associations of 573,027 CpG sites in 
5,101 individuals, and 249 plasma proteins in two cohorts, one of 909 and the other of 998 
individuals. In addition, using mass-spectrometry, I assessed the genetic association for 
4,433 proteins in the peripheral blood mononuclear cells of 251 individuals. These analyses 
generated a wealth of genetic associations that were further exploited in a number of ways, 
including Mendelian Randomisation, co-localisation with expression (RNA) quantitative trait 
loci (eQTLs), and enrichment analyses. 
 
Using the genetic associations of the 249 plasma proteins, I performed proteome-by-
phenome Mendelian Randomisation and demonstrated 509 putative causal links between 
various proteins and outcome diseases and traits, including such links to cardiovascular 
disease and schizophrenia. However, total plasma protein abundance derives from multiple 
sources and is unlikely to be representative of any single cell-type or tissue. Therefore, in an 
exploratory analysis, I demonstrate the feasibility of studying the cellular proteome of 
peripheral blood mononuclear cells using mass-spectrometry. Mass-spectrometry 
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proteomics provides a depth of coverage of the proteome not currently possible with other 
technologies, as well as enabling the possibility of additional complementary future 
analyses, for example, that of protein post-translational modifications. 
 
I identified potential molecular intermediates mediating inter-chromosomal methylation 
quantitative trait loci (meQTLs) by assessing their co-localisation with locally- acting eQTLs. I 
found strong enrichment for genes encoding C2H2-ZF transcription factors, especially those 
containing a Krüppel associated box (KRAB) domain. In addition, I identified DNA 
methylation affected by dominance inter-chromosomal meQTL in the binding sites of many 
transcription factors and associated proteins. 
 
Collectively, these analyses represent an assessment of the genetic control of plasma 
proteins and DNA methylation, with projection onto disease and other human traits. In 
addition, I lay the foundation for a much larger population-scale analysis of the cellular 
proteome of peripheral blood mononuclear cells to unprecedented depth: data acquisition 




How a cell controls the amount of each different protein it makes is far from fully 
understood. However, this is an important question because DNA variation between people 
that is associated with a disease is also commonly associated with protein abundance. 
Proteins are often viewed as the molecular machines of the cell, and different cell-types 
need different sets of these machines to perform their specific functions. Currently, there is 
great interest in understanding how DNA differences ultimately determine traits, such as 
height, weight, or heart disease risk. The path from genotype (the DNA of an individual) to 
outcome trait (e.g. disease) is often long, and over a complex regulatory landscape. This 
landscape is sculpted by many features, such as other proteins and chemical changes to the 
DNA itself (i.e. epigenetics). 
 
Understanding the effects of DNA variation, particularly on proteins and their production, is 
important because it identifies points on the road between a DNA change and disease 
where it may be possible to intervene with a new medication. 
 
I have investigated the effects of genetic differences between people on protein amount in 
their plasma (part of the blood), and this has allowed me to predict protein amount in other 
large genetic studies of various diseases. In many cases, this led to evidence that changes in 
the abundance of a specific protein contribute to causing disease. In addition, I explored the 
practicality of directly measuring protein amounts in blood cells themselves, rather than in 
the plasma, and present promising initial results. 
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In a further study, I located where epigenetic changes are affected by DNA differences. By 
combining these results with those from previously published studies, I predicted many 
proteins likely to cause these epigenetic changes. Given the genome-wide coverage of the 
epigenetic data, these results provide a map of the whole landscape between genetic 
variation and outcome trait. 
 
Together, these results represent an analysis of the effects of DNA variation within the cell, 
not only probing the underlying biology of the system, but also assisting in the identification 







Work performed either as part of this thesis, parallel, or supplemental to it has formed part 
of one peer-reviewed first author publication 1, three non-first author peer-reviewed 
publications 2–4, one first author pre-print 5, and two non-first author pre-prints 6,7. In 
addition to this, I have contributed work to the GoDMC 8 and SCALLOP 9 consortia. 
 
The pre-print “Proteome-by-phenome Mendelian Randomisation detects 38 proteins with 
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With respect to the assessment of organism level phenotypes, we are living in an era of 
multitudinous genome-wide association (GWA) studies. The assessment of the correlation 
between standard quantitative traits (e.g. height) or diseases (e.g. coronary heart disease 
risk), and millions of genetic variants is now routine 10. One striking finding to come from the 
years of genome-wide association (GWA) study of disease associated genetic variation is 
that the vast majority of disease associated DNA variation is in non-coding regions. It has 
been estimated that approximately 93% of common disease-associated genetic variation 
resides in non-coding regions 11. However, the mechanistic downstream consequences of 
this variation are not well established. In order to try and bridge this gap, there is a growing 
movement towards ‘-omics’ studies of intermediate phenotypes 12–14. In this context, 
‘intermediate’ refers to any trait that could be considered to reside on the pathway 
between genetic variation and an outcome trait of interest (be that a disease or other 
‘complex’ trait, or even another ‘-omic’ trait). These studies, as far as is practical, attempt to 
comprehensively assess a given type of biological molecule, for example, proteomics 
(proteins), methylomics (DNA CpG methylation sites), and transcriptomics (RNA). These 
types of studies pose new challenges relating to their assessment and understanding. 
However, by tying a molecular and a disease / anthropometric phenotype together by their 




When a genetic locus is found to control the value of a quantitative trait, it is termed a 
quantitative trait locus (QTL). This nomenclature has been extended to include those 
genomic loci associated with intermediate traits, for example, genomic locations associated 
with DNA CpG methylation are termed meQTL, and those associated with protein 
abundance, pQTL. However, not all single nucleotide polymorphism within the locus are 
likely to be causal. For example, it is perfectly plausible that there is only one variant 
exerting an effect within a locus. However, others variants found within the locus, that are 
not directly causal, may still be found to have an association with trait. In this case, this is 
due to linkage disequilibrium with a causal variant. 
 
Despite the increased complexity, the analysis of intermediate traits enables one to begin to 
obtain mechanistic understanding of the consequences of this non-coding variation. For 
example, it is estimated that about a third of disease and trait associated SNPs are also 
distantly- acting meQTL 15. It has previously been shown that, on a small scale, this is due to 
the distantly- acting meQTL affecting the local production of a nearby transcription factor, 
and it is the transcription factor itself that then goes on to exert effects on distant CpGs sites 
15. This example neatly demonstrates how various intermediate traits can be interlinked and 
mechanistic understanding advanced. 
 
Throughout this thesis, I have chosen to describe QTL as locally- or distantly- acting if 
discrimination was based upon genomic location, and cis- or trans- if the discrimination was 
based upon molecular mechanism (i.e. acting on the same DNA molecule or not). Note that 
all inter-chromosomal links would be classified as both distant- and to act in trans-. 
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However, whilst most local- variation may well act in cis, it does not necessarily do so. This 
situation becomes even more complex for distant- links within a single chromosome where, 
without additional experimentation, the molecular mechanism underlying the relationship 
(i.e. cis- vs. trans-) remains ambiguous. 
 
In this thesis, I perform assessment of pQTL from plasma, cellular pQTL in peripheral blood 
mononuclear cells (PBMCs), and meQTL from whole blood, the backgrounds of which I 
briefly review here. 
 
The human proteome 
It is estimated that there are around 20,000 16–18 genes encoded in the human genome. 
However, there are many more potential protein products: due to alternative splicing and 
post-translational modification, for example. True coverage of all protein species is 
technologically impossible at the present time, and is unlikely to become so in the near 
future. However, the term ‘proteomics’ tends to be used (rather loosely) for studies 
assessing more than a hundred or so proteins simultaneously, a convention I do not attempt 
to redress here. 
 
Classically, the difficulty with traditional measurements of protein abundance, for example 
western blotting, is that they are not easily scalable. Current technologies used to assess the 
proteome at population-scales can broadly be categorised into two groups: antibody-based 
assays, and aptamer-based assays. Currently, to the best of my knowledge, the deepest 
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population-scale proteomics study available is that of Sun et al. from 2018 14, who assessed 
3,622 plasma proteins in 3,301 healthy participants. However, due to the subjective 
selection of proteins for inclusion on an array, array-based technologies are not a panacea 
for this type of work. It also remains an open question as to how representative the 
proteome of plasma is of any single cell-type or tissue. One might suspect, given that the 
blood is one of the principal transport mechanisms available to the body: responsible for 
oxygen delivery, metabolite transport, and the carriage of many cells in its own right – that 
it is unlikely to be a close proxy of the proteome of any specific cell-type or tissue. Due to 
the multiple origins of proteins in the plasma, proteins that are expressed in a limited subset 
of cell-types are likely to be diluted when added to the milieu of the plasma, further 
compounding difficulties in their detection. 
 
An alternative approach is that of mass-spectrometry. When using cell-lysate, the depth of 
coverage possible with high-performance liquid-chromatography mass-spectrometry is 
unparalleled by current array-based technologies. This technology is now mature enough to 
begin to apply at population-scales and some early mass-spectrometry-based genome-wide 
association studies are beginning to emerge: for example, in induced pluripotent stem cells, 
Mirauta et al. 19 revealed over 700 human pQTL in induced pluripotent stem cells (false 
discovery rate (FDR) <0.10). 
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The human methylome 
Cytosine methylation of DNA is an important epigenetic modification in Eukaryotes and, 
when disturbed, has been associated with numerous diseases (be that as cause or 
consequence) 12,20,21. In molecular terms, it is the covalent addition of a methyl group to the 
DNA base cytosine, resulting in 5-methylcytosine. In humans, there is generally a paucity of 
CpG dinucleotides out with of ‘islands’ of relatively high CpG content, often associated with 
gene promoters 22. It has been shown that, in humans, 5-methylcytosine predominantly 
occurs at CpG dinucleotides and, outside of CpG islands (where the situation is more 
complex), is wide-spread across the genome 23. 
 
Recent technological advances have enabled the production of array-based technologies to 
assess the DNA CpG methylation status at >500,000 sites simultaneously. Indeed, previous 
smaller GWA studies have been performed on DNA methylation 12,21, with some degree of 
success. For example, it has previously been demonstrated that the phenotypic variation 
explained by meQTL is substantial. In one study, 8% of locally- acting meQTL explained more 
than 50% of the variation of the CpG to which they corresponded 12. In that same study, 
despite fewer distantly- acting meQTL explaining very large proportions of CpG variance 
when compared to locally- acting meQTL, an enrichment of distantly- acting meQTL was still 




Standard GWA studies commonly focus on the estimation of allelic effects, that is, the effect 
per additional encoded allele. Using this model, these studies have been fantastically 
successful at identifying disease and trait associated genetic variation. However, this is not 
the only model it is possible to fit. For example, in chapter 4, I fit a model that explicitly 
includes both an additive and dominance effect of the encoded allele. Given the increased 
complexity of the model as well as difficulties of detecting dominance variation (as 
discussed in the chapter), molecular traits represent a bastion where fitting this model may 
be useful, in particular, given the predicted, bi-allelic effects of diffusible mediators. 
 
What is the utility of these genetic associations? 
Co-localisation of effects at a given locus can give information about the likely molecular 
actors orchestrating the relationship between genotype and phenotype. For example, IL6 
receptor signalling and coronary heart disease 24,25. As mentioned above, methods exist – 
such as Mendelian Randomisation (MR) 26,27 – that can combine GWAS and ‘-omics’ to infer 
disease risk-altering molecules. It is worth remembering that molecules identified as 
causally contributing to disease risk are potential drug targets, and their identification may 
have profound effects on the therapeutics of the future. It is estimated that genetic 
evidence in support of a protein’s candidature as a drug target could double its probability 
of success in clinical development 28. 
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Genetic differences between individuals can affect the abundance of molecular 
intermediates: including protein (pQTL), and DNA CpG methylation (meQTL). The phrase 
‘genetic control’ is used within this thesis to mean this type of direct link between genotype 
and phenotype. Despite leveraging a priori biological knowledge as the justification for 
doing this, it has often not directly been observed, and therefore not absolute: this should 
be considered wherever this phrase is used. Given this caveat, if an allele causes a change in 
the mean abundance of a protein then, within the assumptions of MR (discussed in 
Chapters 2 and 5), this implies that any observed association of the allele with disease risk is 
due to differences in mean protein level: that is, the protein causally contributes to disease 
risk. In essence, MR is akin to a naturally occurring randomised control trial. For MR, local 
protein quantitative trait loci (pQTLs) are almost ideal instrumental variables: they have 
large effect-sizes and highly plausible biological relationships with protein level and, when 
used, may provide quantitative information on directly druggable protein targets. 
 
Thesis outline 
Chapter 1: Introduction 
Chapter 2: Plasma array-based proteomics 
In this chapter, I present an unpublished paper entitled “Linking protein to phenotype with 
Mendelian Randomisation detects 38 proteins with causal roles in human diseases and 
traits” 5. Author contributions are included within the paper itself; however, to summarise: I 
performed the GWA of the proteins, in both cohorts, and downstream analyses (other than 
the ChEMBL search, and the composition of Figure2d). 
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In the manuscript I present proteome-by-phenome MR as a paradigm for large-scale drug 
target discovery. This is a topic of great interest to both academia and the pharmaceutical 
industry. Using proteome-by-phenome MR, I report 509 robust protein-outcome links, each 
likely to causally contribute to the outcome trait. These include: FABP2 in cardio-vascular 
disease, SHPS1 in schizophrenia, and IL6R in atopy. This study and its results are analogous 
to 509 randomised control trials, in humans, in which each reports a significant finding. 
 
In order to perform proteome-by-phenome MR I undertook genome-wide association with 
plasma concentration of 249 proteins in two European cohorts: each of >850 individuals, 
discovery and replication. I used outcome data on 846 traits and diseases, from published 
studies of UK Biobank 29 and others (see Chapter), to assess 54,144 exposure-outcome pairs. 
I identified 38 proteins inferred to causally contribute to 509 significant exposure-outcome 
pairs and, for significant outcomes from UK Biobank, I also tested whether results had 
consistent MR effect estimates across each locus, or not. 
 
Proteome guided MR reveals novel candidate targets for drug discovery and offers insights 
into the likely side-effects of therapeutic agents that target a particular molecular entity. 
This approach is less expensive, less time-consuming, and more scalable than randomised 
control trials, and more physiologically relevant than model organism studies. 
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Chapter 3: Cellular mass-spectrometry based proteomics 
Here I present the results of the first phase of a much larger project to assess the proteome 
of peripheral blood mononuclear cells at both unprecedented depth, and scale in 
Generation Scotland. I conceived, designed, and executed this project with the help and 
support of the IGMM mass-spectrometry team, Generation Scotland, and my supervisory 
team. Generation Scotland had already collected the PBMCs and undertaken genotyping 
and associated QC. 
 
Ultimately, this project will include the proteomes of the peripheral blood mononuclear 
cells of over 850 individuals: in the chapter I present the results from the first phase of 251 
individuals. I identify 4,433 proteins, each found in one hundred or more samples, at a false 
discovery rate of less than one percent. To the best of my knowledge, this is already the 
deepest assessment of the proteome of peripheral blood mononuclear cells, and the 
broadest population-scale assessment of the proteome of any primary cell-type. The 
direction and magnitude of effect of my results are broadly consistent with those obtained 
for RNA in whole blood, yet have both incomplete overlap, and imperfect correlation. 
Comparison to plasma protein quantitative trait loci hints at unique genomic signatures of 
control, commensurate with the differing origins of the proteins in peripheral blood 
mononuclear cells and the plasma. 
 
I assess those proteins for which I identified a significant (FDR <0.05) locally- acting pQTL (n 
= 108) for causal contribution to rheumatoid arthritis risk and identify 7 proteins potentially 
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involved in its pathogenesis (HLA-DQA1, NELFE, PADI4, HLA-B, RNASET2, PADI2, and HLA-F), 
including both members (PADI2 and PADI4) of the ‘histone H3-R26 citrullination’ pathway 
(GO:0036413). In reviewing the association of the lead-SNP at the locally- acting pQTL 
associated with the proteins PADI2 and PADI4 across their respective genes, I demonstrate 
an association of the lead-pQTL SNP with DNA methylation across the gene of the protein to 
which the SNP is associated, representing a potential method to assess for potential 
pleiotropy. 
 
Chapter 4: DNA CpG methylation 
I perform a genome-wide association study of >500,000 CpG sites, using the Illumina EPIC 
array, in 5,101 individuals from Generation Scotland and demonstrated that the relationship 
between transcription factors and inter-chromosomal meQTLs is very strong. 
 
Using locally- acting expression quantitative trait loci (eQTL) from the Genotype-Tissue 
Expression (GTEx) project (v6p) 13 to identify genes locally impacted by the SNPs of inter-
chromosomal meQTLs included 5.8% of all known human transcription factors: including 
9.7% of all known human C2H2 zinc-finger (C2H2-ZF) transcription factors, and 14.9% of all 
known human Krüppel associated-box (KRAB) containing transcription factors. This is a 
significant enrichment when compared to a random background of eQTL from the GTEx 
(v6p) 13 project. In addition, the proportion of C2H2 and KRAB containing transcription 
factors in the set of transcription factors identified is significantly enriched when compared 
to all known human transcription factors 30. 
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The KRAB domain is classically considered a transcriptional repressor and it has previously 
been shown that the DNA methylation induced by KRAB domain containing transcription 
factors can spread from their binding sites 31,32. Consistent with this, I demonstrate an 
association with increased dominance inter-chromosomal genetic control of DNA CpG 
methylation for CpGs located in the binding sites of many transcription factors, DNA binding 
proteins, and their co-factors: not limited to those I identify as directly associated with inter-
chromosomal meQTL. 
 
Generation Scotland and STRADL had already performed genotyping and imputation, and 
the genesis of the DNA CpG methylation data. Quality control and residualisation of the 
methylation data was performed by Rosie Walker and Yanni Zeng. The text describing the 
genotyping and measurement of methylation subsections of the Methods section of 
Chapter 4 is partially shared with the GoDMC manuscript. I created the additive / 
dominance GWA program and pipeline, and performed all downstream analyses of these 
results. 
 
Chapter 5: Conclusion 






2. Plasma array-based proteomics 
Pre-material 
This chapter comprises an edited version of a revised pre-publication paper: a pre-print of 
which is available on BioRxiv: https://www.biorxiv.org/content/10.1101/631747v1. 
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Abstract. To efficiently transform genetic associations into drug targets requires evidence 
that a particular gene, and its encoded protein, contribute causally to a disease. To achieve 
this, we employ a three-step proteome-by-phenome Mendelian Randomisation (MR) 
approach. In step one, 154 protein quantitative trait loci (pQTLs) were identified and 
independently replicated. From these pQTLs, 64 replicated locally-acting variants were used 
as instrumental variables for proteome-by-phenome MR across 846 traits (step two). When 
its assumptions are met, proteome-by-phenome MR, is equivalent to simultaneously 
running many randomised controlled trials. Step 2 yielded 38 proteins that significantly 
predicted variation in traits and diseases in 509 instances. Amongst the 271 instances from 
GeneAtlas (UK Biobank), 77 showed little evidence of pleiotropy (step three).  Results were 
wide ranging: including, for example, new evidence for a causal role of tyrosine-protein 
phosphatase non-receptor type substrate 1 (SHPS1; SIRPA) in schizophrenia, and a new 
finding that intestinal fatty acid binding protein (FABP2) abundance contributes to the 
pathogenesis of cardiovascular disease. We also demonstrated confirmatory evidence for 
the causal role of four further proteins (FGF5, IL6R, LPL, LTA) in cardiovascular disease risk. 
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Author summary. The targets of most medications prescribed today are proteins. For many 
common diseases our understanding of the underlying causes is often incomplete, and our 
ability to predict whether new drugs will be effective is remarkably poor. Attempts to use 
genetics to identify drug targets have an important limitation: standard study designs link 
disease risk to DNA but do not explain how the genotype leads to disease. In our study, we 
made robust statistical links between DNA variants and blood levels of 249 proteins, in two 
separate groups of Europeans. We then used this information to predict protein levels in 
large genetic studies. In many cases, this second step gives us evidence that high or low 
levels of a given protein play a role in causing a given disease. Among dozens of high-
confidence links, we found new evidence for a causal role of a protein called SHPS1 in 
schizophrenia, and of another protein (FABP2) in heart disease. Our method takes advantage 
of information from large numbers of existing genetic studies to prioritise specific proteins 




An initial goal of drug development is the identification of targets – in most cases, proteins – 
whose interaction with a drug ameliorates the development, progression, or symptoms of 
disease.  After some success, the rate of discovery of new targets has not accelerated 
despite substantially increased investment33. A large proportion of drugs fail during the last 
stages of development – clinical trials – because their targets do not alter whole-organism 
phenotypes as expected from observational and other pre-clinical research34. Genetic 
approaches to drug development35 offer a distinct advantage over observational studies. It is 
estimated that by selecting targets with genetic evidence, the chance of success of those 
targets doubles in subsequent clinical development28. For example, a recent study found 
that 12% of all targets for licenced drugs could be rediscovered using GWA studies36. Indeed, 
there have been a number of recent high-profile successes prioritising therapeutic targets at 
genome-wide scales37,38. Nevertheless, the genetic associations of disease are often still not 
immediately interpretable39 and many disease-associated variants alter protein levels via 
poorly understood mechanisms. 
 
When combined with proteomic data, however, genetics can provide insight into proteins 
that likely impact disease pathogenesis. Mendelian Randomisation (MR) in this context uses 
genetic variants to estimate the effect of an exposure on an outcome, using the randomness 
by which alleles are allocated to gametes to remove the effects of unmeasured confounding 
between a protein and the outcome40.  Given a set of assumptions, detailed below, this 
approach is analogous to a naturally-occurring randomised controlled trial. Using a genetic 
variant that predicts the abundance of a mediating molecule, MR tests the hypothesis that 
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this molecule plays a causal role in disease risk. To do so it takes advantage of the patient’s, 
or participant’s, randomisation at conception to this molecule’s genetically-determined 
level. Under this model, it is possible to use population level genetic information to draw 
causal inference from observational data.  
 
Proteome-by-phenome MR, in common with all other MR studies, has three key 
assumptions that must be fulfilled to ensure the legitimacy of any causal conclusions 
drawn26: 1) that the SNP is associated with the exposure of interest, 2) that the SNP is 
independent of any confounders, and 3) that the SNP does not influence the outcome of 
interest, except via the exposure variable. 
 
A common concern in the use of MR is that the genetic variant is linked to the outcome 
phenotype via an alternative causal pathway. In a drug trial this would be analogous to an 
intervention influencing a clinical outcome through a different pathway than via its reported 
target. To avoid pursuing drugs that target an irrelevant molecular entity, and hence that 
have no beneficial effect, we applied MR to proteins – the likely targets of therapy – and 
limited our genetic variants to those that are locally-acting protein quantitative trait loci 
(pQTLs). This approach provides stronger supporting evidence for a causal role of the protein 
on disease than relying on the proximity of a disease-associated genetic variant to a nearby 
gene, or using mRNA abundance as a proxy for protein abundance19. 
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Previous studies have also leveraged the increased availability of pQTL data for drug target 
and biomarker discovery14,41–46. For example, in one of the largest pQTL studies to date, Sun 
et al.14 applied an aptamer-based approach (rather than an antibody-based assay as here) to 
perform extensive co-localisation analyses and used MR to assess the causal contribution of 
IL1RL1–IL18R1 locus to atopic dermatitis, and that of MMP12 to coronary heart disease. In 
the study presented here, we attempt to systematically use MR to link protein to outcome 
trait by taking a three-step approach. Firstly, identifying replicated pQTL in our two 
European cohort studies before then using these in a systematic MR approach with two 
large sets of GWA study data. In a final step, we test results from one of these sets for their 
consistency with a single underlying causal variant (affecting both variation in protein 
concentration and outcome phenotype). 
 
Overall, our proteome-by-phenome MR approach assessed the causal role of 64 proteins in 
846 outcomes (e.g. diseases, anthropomorphic measures, etc.), identifying 38 as causally 
contributing to human diseases or other quantitative traits. Notwithstanding the 
assumptions of MR, obtaining evidence for causality from studies such as this is far more 
scalable than via randomised controlled trials, and is more physiologically relevant than 




The abundance of an individual protein can be associated with DNA variants that are either 
local or distant to its gene (termed local- and distal-pQTLs, respectively). In many respects, 
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locally-acting pQTLs are ideal instrumental variables for MR: they tend to have large effect 
sizes, have highly plausible biological relationships with protein level, and provide 
quantitative information about (often) directly druggable protein targets. This is in contrast 
to distal pQTLs, where the pathway through which they exert their effects is generally 
unknown, with no a priori expectation of a direct effect on a single target gene. 
 
We assayed the plasma levels of 249 proteins using high-throughput, multiplex 
immunoassays and then performed genome-wide association of these levels in each of two 
independent cohorts (discovery and replication) of 909 and 998 European individuals who 
had previously been genotyped. 
 
Lead-SNPs, defined as the variant with the smallest p-value and accounting for linkage 
disequilibrium (Methods), were identified for each protein. As expected, pQTLs were highly 
concordant between the two independent cohorts (Supplementary Table 1). 121 pQTL were 
identified in the discovery dataset, and, of these, 90.1% (109/121) were successfully 
replicated after accounting for multiple testing in both the discovery and replication. 
However, this was felt to be excessively stringent with respect to instrument identification, 
and a more permissive threshold of 5x10-8 was therefore used in the discovery cohort. Of 
the 209 lead-SNPs identified in the discovery cohort at this threshold, 154 were successfully 
replicated (accounting for multiple testing during replication and with consistent direction of 
effect). These represented pQTLs for 82 proteins, all but two proteins were successfully 
mapped to an autosomal gene (Ensembl GRCh37). The majority of these proteins (64/80; 
80%) had a replicated lead-SNP within 150kb of the gene encoding the protein (Figure 1). 
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The variant to use as the instrumental variable for each protein was selected as the 
replicated lead-SNP lying within 150kb of the gene encoding the protein with the lowest 
significant p-value in the discovery set (Methods). Increasing this proximity threshold to 
within 1Mb added a single protein only. Further support for the validity of these instruments 
was provided through comparison with the results of Sun et al.14 and GTEx13 (Methods): of 
the instrumental variables identified (a) 52% (14/27) of those comparable were in high LD 
(r2>0.8) with the results of Sun et al. (Supplementary Table 2), and (b) 30% (16/54) were also 
called as significant expression QTLs (eQTLs; Bonferroni correction; Supplementary Table 3) 
in GTEx – in keeping with previous studies14. 
 
Proteome-by-phenome Mendelian Randomisation 
Proteome-by-phenome MR was then applied to 54,144 protein-trait pairs obtained from 
these 64 replicated local-pQTLs and 778 traits obtained from GeneAtlas (UK Biobank)29, and 
68 traits from 20 additional genome-wide association (meta-analysis) studies47–66 identified 
through Phenoscanner67,68 (Figure 1; Supplementary Table 4; Methods). Phenoscanner 
studies were additionally analysed because, although the UK Biobank cohort is large 
(~500,000 individuals), for many diseases the number of affected individuals is small, 
resulting in low statistical power (Methods). 
 
Proteome-by-phenome MR yielded 271 significant protein-trait pairs (FDR <0.05) in 
GeneAtlas, and 238 significant (FDR <0.05) pairs using Phenoscanner data. Thirty-two of the 
64 proteins were causally implicated for one or more traits in GeneAtlas, and 36 of 64 in the 
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Phenoscanner studies’ traits. GeneAtlas and Phenoscanner traits are not mutually exclusive, 
and some of the Phenoscanner studies included UK Biobank data. Nevertheless, a majority 
(60%; 38/64) of the proteins were implicated in one or more traits (e.g. IL6R: as discussed 
below; Supplementary Table 5 and Supplementary Table 6). 
 
For some of these inferences, genetic evidence of an association between a protein and 
phenotype has previously been proposed based simply on physical proximity of the genes to 
GWA intervals. However, in actually measuring protein products we go well beyond genetic 
proximity-based annotation of GWA hits: (a) we provide direct evidence that a SNP actually 
changes the abundance of a protein, and (b) notwithstanding the assumptions of MR, that 
the change in protein abundance observed is consistent with a causal effect of the protein 
on outcome trait variation. In addition, notwithstanding the different significance criteria, 
nearly two-thirds (62%; 318/509) of the significant (FDR <0.05) MR associations between 
protein and outcome were not matched by significant (p-value <5x10-8) association of the 
DNA variant to outcome.  
 
Heterogeneity of effect-size estimates 
For GeneAtlas results, we use HEIDI to test for heterogeneity of MR effect estimates 
between the lead variant (the primary instrument) and those of linked variants. More 
specifically, this method tests the null hypothesis that the observed MR result is consistent 
with a single causal variant27, explicitly accounting for the LD structure across the locus. In 
these results, 77 of 271 survived the HEIDI heterogeneity test (p-value >0.05).  These 77 
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proteins thus have: (1) high-quality evidence of association to a DNA variant that provides 
congruent predictions for both plasma protein levels and disease risk or trait, and (2) a low 
risk of pleiotropy, because of both the physical proximity of the pQTL to the protein’s gene, 
and their survival of the HEIDI test (Supplementary Table 5). These 77 relationships provide 
the most robust evidence that the level of the protein directly alters disease risk or trait. 
 
Nevertheless, we emphasise that all 509 causal inferences (271 from GeneAtlas29 and 238 
from studies identified through Phenoscanner67,68; Figure 2, and Supplementary Table 5 and 
Supplementary Table 6), even those consistent with heterogeneity (GeneAtlas only), remain 
potential high quality drug targets. An appropriate interpretation of this result is that there 
are 271 potentially causal links identified in GeneAtlas, with additional support for 77 based 
on results of the HEIDI analysis. This is because the HEIDI heterogeneity test (Figure 1) is 
susceptible to type I errors (i.e. false positives) in the context of this study. The method can 
report significant heterogeneity where there is, in fact, none if: (a) there are multiple causal 
variants present within a locus, or (b) there are differences in the LD structure among the 
discovery pQTL GWA population (used for lead-SNP selection), the replication pQTL GWA 
study population (used for effect-size estimation), the outcome trait GWA study population, 
or that of the LD reference. Finally, it is worth noting that we applied the HEIDI test in a 
conservative manner: a significant HEIDI test implies heterogeneity yet we did not apply a 
multiple testing correction. Applying a Bonferroni correction (271 tests) to the HEIDI p-value, 




Tractability of the proteins assessed as therapeutic targets 
Of the 32 proteins for which we identified a significant MR association in GeneAtlas 
(Supplementary Table 5), we found 1,319 compounds (Supplementary Table 7) associated 
with 10 proteins in ChEMBL. Of these compounds, 10 have already been tested in phase 2, 
or greater, trials: targeting DLK1, LPL, and LGALS3. 
 
Our results draw causal inference between the plasma concentration of specific proteins and 
many diseases and outcome phenotypes. For example, we provide supporting evidence for a 
role of IL4R in asthma, IL2RA in thyroid dysfunction, and IL12B in psoriasis (Figure 2), as well 
as many cellular phenotypes, such as Transferrin receptor protein 1 (encoded by TFRC) in 
mean corpuscular haemoglobin. Multiple disease endpoints exist to which we have found a 
MR link and, additionally, for some diseases we have causal links from multiple proteins 
(Figure 2a, b; Supplementary Table 5 and Supplementary Table 6). 
 
Many-to-One: multiple proteins link to asthma. 
Asthma is an inflammatory condition affecting the airways. Using GeneAtlas data, our 
analysis finds 5 proteins – all interleukin receptors – whose levels causally contribute to 
asthma disease risk: IL1RL1, IL1RL2, IL2RA, IL4R, and IL6R (Figure 2d). Prior links between 
these proteins and asthma or atopy exist (IL1RL169,70 and IL1RL214, IL2RA64,71, IL4R72, and 
IL6R64,72–76), albeit not necessarily strong evidence for a causal link. Of these, IL6R was not 
significantly heterogeneous in HEIDI testing (p >0.05), and also IL4R if accounting for 
multiple tests (p >0.05/271). Given the association between eosinophils and asthma, it is 
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worth noting that IL1RL1, IL1RL2, IL2RA, and IL4R are all linked to ‘Eosinophil count’ and 
‘Eosinophil percentage’ in GeneAtlas. Whilst not a true replication, due to the use of UK 
Biobank data in both GeneAtlas and some of the Phenoscanner studies, Figure 2d reveals 
strong concordance between the MR links identified between the two. Of the 12 
Phenoscanner studies reporting significant MR links in this study47,49–51,53,55,57,60,61,64–66, 5 
include UK Biobank data from ~150,000 individuals49,55,57,65,66, and only one uses the full UK 
Biobank release61. 
 
One-to-Many: Linking IL6R levels to atopy, rheumatoid arthritis, and coronary artery 
disease. 
We also found evidence for a causal association between plasma IL6R abundance and 
coronary artery disease (CAD), atopy, and rheumatoid arthritis (Figure 2, Supplementary 
Table 5, and Supplementary Table 6). We note previous support for these inferences: for 
example, tocilizumab (a humanized monoclonal antibody against IL6R protein) is in clinical 
use for treating rheumatoid arthritis77, prior MR evidence has linked elevated levels of 
soluble IL6R to reduced cardiovascular disease24,25, and, as discussed above, there is 
previous genetic evidence of a link between IL6R and atopy64,72–76. 
 
SHPS1 and schizophrenia 
Three proteins were implicated in the pathogenesis of schizophrenia: (i) Tyrosine-protein 
phosphatase non-receptor type substrate 1 (SHPS1; SIRPA) – Figure 3, (ii) Tumour necrosis 
factor receptor superfamily member 5 (CD40), and (iii) Low affinity immunoglobulin gamma 
Fc region receptor II-b (FCGR2B). 
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Focussing on SHPS1, it is highly expressed in the brain, especially in the neuropil (a dense 
network of axons, dendrites, and microglial cell processes) in the cerebral cortex 
(https://v18.proteinatlas.org/ENSG00000198053-SIRPA/tissue 78–80; accessed 01 Apr 2019), 
and co-localises with CD47 at dendrite-axon contacts81. Mouse models in which the SHPS1 
gene is disrupted exhibit many nervous system abnormalities, such as reduced long term 
potentiation, abnormal synapse morphology and abnormal excitatory postsynaptic potential 
(MGI: 5558020 82; http://www.informatics.jax.org/; v6.13; accessed 01 Apr 2019). Other 
mouse and rat models link CD47 to sensorimotor gating and social behaviour phenotypes83–
87. In addition, SHPS1 mediates activity-dependent synapse maturation82 and may also have 
a role as a “don’t eat me” signal to microglia88. SHPS1 levels tend to be lower in the 
dorsolateral prefrontal cortex of schizophrenia patients89. Finally, the observed effect of 
SHSP1 on schizophrenia was not significantly heterogeneous in the results of the 
Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) (p-value 0.53). 
 
FABP2 and coronary artery disease 
Four other proteins, in addition to IL6R, were identified as contributing to CAD pathogenesis, 
namely FABP2, FGF5, LPL, and LTA (Figure 2). FGF5, LPL, IL6R, and LTA had been implicated 
previously49,90,91, whereas FABP2 had more limited prior evidence for its involvement. 
 
pQTL analysis identified two lead DNA variants in close proximity (<150kb) to the FABP2 
gene. Using SNP rs17009129, we find a causal link between FABP2 abundance and CAD (p-
value 1.1x10−4; FDR <0.05; βMR -0.11; seMR 0.028; βMR and seMR units: log(OR)/standard 
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deviation of residualised protein concentration) without significant heterogeneity (p-value 
0.24) which suggests shared causal genetic control. Furthermore, a second independent SNP 
(LD r2 <0.2; rs6857105) replicates this observation (MR p-value 5.0x10−4; HEIDI p-value 0.34; 
βMR -0.17; seMR 0.047). Both SNPs (rs17009129, and rs6857105) fell below genome-wide 
significance (p-value <5x10−8) in the full meta-analysis of van der Harst61 on CAD. 
Consequently, this is the first time, to our knowledge, that variants associate with FABP2 
abundance have been demonstrated to contribute causally to CAD pathogenesis. 
 
Discussion 
Proteome-by-phenome MR efficiently and robustly yields evidence for proteins as drug 
targets. It offers a data-driven approach to drug discovery using population-level data, and 
quantifies the strength of evidence for causation. Previous studies have made successful 
forays into the use of pQTL in mapping protein variation onto disease14,41–46, and both the 
coverage of the proteome and the availability of disease and trait GWA study results are 
ever increasing. By using the lead variants of locally-acting pQTLs as instrumental variables, 
we focused specifically on a subset of functionally relevant variants for those proteins under 
study: this choice reduced the multiple testing burden when compared to genome-wide 
scans for associations of the outcome trait. 
 
A potential problem with antibody- and aptamer-based assays is that any perturbation to 
binding, such as a change to an epitope, appears incorrectly as a change in abundance. In 
the absence of a well-defined reference, we cannot exclude the possibility that some of the 
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pQTL we have called indicate epitope changes rather than changes in protein abundance. 
However, in each case, a bona fide biological association does exist between the genetic 
variant and the protein. With respect to MR, this would change the biological interpretation 
of the exposure only: protein abundance or sequence isoform, for example.  
 
In addition, proteome-by-phenome MR has inherent limitations. First, a true positive MR 
association in our analysis implies that any intervention to replicate the effect of a given 
genotype would alter the relevant phenotype. Nevertheless, this association is informative 
neither of the time interval, during development for example, nor the anatomical location in 
which an intervention would need to be delivered. Second, pleiotropic effects cannot be 
excluded entirely without (unachievable) quantification of every mediator. Third, the 
abundance of a protein in plasma may be an imperfect proxy for the effect of a drug 
targeting that protein at the level of a whole organism. Finally, plasma abundance does not 
necessarily reflect activity. For example, a variant may cause expression of high levels of an 
inactive form of a protein. Or, for proteins with both membrane-bound and unbound forms, 
the MR direction of effect observed from quantifying soluble protein abundance may not 
reflect that of membrane-bound protein. For many membrane-bound proteins, a soluble 
(often antagonistic) form exists that is commonly produced through alternative splicing or 
proteolytic cleavage of the membrane-bound form. Based on 1,000 Genomes92,93 data, the 
variant we use to predict IL6R level, rs61812598, for example, is in complete LD with the 
missense variant rs2228145 whose effects on proteolytic cleavage of the membrane-bound 
form and alternative splicing have been examined in detail94. Carriers of the 358Ala allele at 
rs2228145 tend to have increased soluble IL6R but reduced membrane-bound IL6R in a 
number of immune cell types. Differences between the effects of soluble and membrane-
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bound forms of a protein may be widespread. For example, dupilumab is a monoclonal 
antibody that targets IL4R, a key component of both IL4 and IL13 signalling. It is currently 
under investigation for the treatment of asthma and has shown promising results in both 
eosinophilic and non-eosinophilic asthma95,96. Based on our results, we would have 
predicted that increased levels of IL4R result in a lower risk of asthma (Supplementary Table 
5). This is in contrast to the direction-of-effect due to dupilumab administration. However, 
as with IL6R, IL4R has both a soluble and a membrane-bound form. Encouragingly, despite 
this, a relationship between dupilumab and asthma remains plausible – as evidenced by the 
14 recently completed or ongoing clinical trials to assess the efficacy and safety of 
dupilumab in asthma (as of 26 March 2019, ClinicalTrials.gov). 
 
As well as its utility in identifying potential therapeutic targets for drug development, 
proteome-by-phenome MR also allows for an assessment of potential off-target effects of 
existing pharmacological targets. For example, we predict an effect of IL4R modulation on 
eosinophil count and percentage. This is an association already realised in one of the phase II 
clinical trials investigating dupilumab in asthma: a rise in eosinophil count was observed for 
some patients, even leading to the withdrawal of one patient from the study95. 
 
Conclusions 
In summary, we have identified dozens of plausible causal links by conducting GWA of 249 
proteins, followed by phenome-wide MR using replicated locally-acting pQTLs of 64 
proteins. The approach is statistically robust, relatively inexpensive, and high-throughput. 
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54,144 protein-outcome links were assessed and 509 significant (FDR <0.05) links identified: 
including anthropometric measures, haematological parameters, and diseases. 
Opportunities to discover larger sets of plausible causal links will increase as study sizes and 
pQTL numbers grow. Indeed, whole-proteome versus Biobank GWA Atlas studies will likely 
become feasible as pQTL measurement technologies mature further.   
Methods 
Cohort description. From the islands of Orkney (Scotland) and Vis (Croatia) respectively, the 
ORCADES97 and CROATIA-Vis98,99 studies are of two isolated population cohorts that are both 
genotyped and richly phenotyped. 
The Orkney Complex Disease Study (ORCADES) is a family-based, cross-sectional study that 
seeks to identify genetic factors influencing cardiovascular and other disease risk in the 
isolated archipelago of the Orkney Isles in northern Scotland97. Genetic diversity in this 
population is decreased compared to Mainland Scotland, consistent with the high levels of 
endogamy historically. 2,078 participants aged 16-100 years were recruited between 2005 
and 2011, most having three or four grandparents from Orkney, the remainder with two 
Orcadian grandparents. Fasting blood samples were collected and many health-related 
phenotypes and environmental exposures were measured in each individual. All participants 
gave written informed consent and the study was approved by Research Ethics Committees 
in Orkney and Aberdeen (North of Scotland REC, 26/11/2003). 
The CROATIA-Vis study includes 1,008 Croatians, aged 18-93 years, who were recruited from 
the villages of Vis and Komiza on the Dalmatian island of Vis during spring of 2003 and 2004. 
All participants were volunteers and gave written informed consent. They underwent a 
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medical examination and interview, led by research teams from the Institute for 
Anthropological Research and the Andrija Stampar School of Public Health, (Zagreb, Croatia). 
All subjects visited the clinical research centre in the region, where they were examined in 
person and where fasting blood was drawn and stored for future analyses. Many 
biochemical and physiological measurements were performed, and questionnaires of 
medical history as well as lifestyle and environmental exposures were collected. The study 
received approval from the relevant ethics committees in Scotland (South East Scotland 
Research Ethics Committee, REC reference: 11/AL/0222) and Croatia (University of Split 
School of Medicine Ethics committee, Class:003-08/11-03/-005 No.: 2181-198-03-04/10-11-
0008).  
Both studies complied with the tenets of the Declaration of Helsinki. 
 
Genotyping. Chromosomes and positions reported in this paper are from GRCh37 
throughout. Genotyping of the ORCADES cohort was performed on the Illumina Human Hap 
300v2, Illumina Omni Express, and Illumina Omni 1 arrays; that of the CROATIA-Vis cohort 
used the Illumina HumanHap300v1 array. 
 
The genotyping array data were subject to the following quality control thresholds: 
genotype call-rate 0.98, per-individual call-rate 0.97, failed Hardy-Weinberg test at p-value 
<1x10−6, and minor allele frequency 0.01; genomic relationship matrix and principal 
components were calculated using GenABEL (1.8-0)100 and PLINK v1.90101,102. 
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Assessment for ancestry outliers was performed by anchored PCA analysis when compared 
to all non-European populations from the 1,000 Genomes project92,93. Individuals with a 
mean-squared distance of >10% in the first two principal components were removed. 
Genotypes were phased using Shapeit v2.r873 and duoHMM103 and imputed to the HRC.r1-1 
reference panel104. 278,618 markers (Hap300) and 599,638 markers (Omni) were used for 
the imputation in ORCADES, and 272,930 markers for CROATIA-Vis. 
 
Proteomics. Plasma abundance of 249 proteins was measured in two European cohorts 
using Olink Proseek Multiplex CVD2, CVD3, and INF panels. All proteomics measurements 
were obtained from fasting EDTA plasma samples. Following quality control, there were 971 
individuals in ORCADES, and 887 individuals in CROATIA-Vis, who had genotype and 
proteomic data from Olink CVD2, 993 and 899 from Olink CVD3, and 982 and 894 from Olink 
INF. The Olink Proseek Multiplex method uses a matched pair of antibodies for each protein, 
linked to paired oligonucleotides. Binding of the antibodies to the protein brings the 
oligonucleotides into close proximity and permits hybridization. Following binding and 
extension, these oligonucleotides form the basis of a quantitative PCR reaction that allows 
relative quantification of the initial protein concentration105. Olink panels include internal 
and external controls on each plate: two controls of the immunoassay (two non-human 
proteins), one control of oligonucleotide extension (an antibody linked to two matched 
oligonucleotides for immediate proximity, independent of antigen binding) and one control 
of hybridized oligonucleotide detection (a pre-made synthetic double stranded template), as 
well as an external, between-plate, control (http://www.olink.com/; accessed: 19th June 
2016). 
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Prior to analysis, we excluded proteins with fewer than 200 samples with measurements 
above the limit of detection of the assay. Of the 268 unique proteins reported by Olink, 253 
passed this threshold in ORCADES, and 252 in CROATIA-Vis, with an intersect of 251 
proteins. Protein values were inverse-normal rank-transformed prior to subsequent analysis. 
 
The subunits of IL27 are not distinguished in Olink’s annotation (Q14213, EBI3; and Q8NEV9, 
IL27). However, it has only one significant locus, local to the EBI3 gene (lead variant, 
rs60160662, is within 16kb). Therefore, EBI3 (Q14213) was selected as representative for 
this protein when discussing pQTL location (local/distal) so as to avoid double counting.  
 
The CVD2, CVD3, and INF panels are commercially available from Olink. The proteins on 
these panels were selected by Olink due to a priori evidence of involvement in 
cardiovascular and inflammatory processes. Two proteins, CCL20 and BDNF, have been 
removed at the request of Olink (due to issues with the assay). 
 
Detection of pQTL. Genome-wide association of these proteins was performed using 
autosomes only. Analyses were performed in three-stages. (1) a linear regression model was 
used to account for participant age, sex, genotyping array (ORCADES only), proteomics plate, 
proteomics plate row, proteomics plate column, length of sample storage, season of 
venepuncture (ORCADES only), and the first 10 principal components of the genomic 
relationship matrix. Genotyping array and season of venepuncture are invariant in CROATIA-
Vis and therefore were not included in the model. (2) Residuals from this model were 
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corrected for relatedness, using GenABEL’s100 polygenic function and the genomic 
relationship matrix, to produce GRAMMAR+ residuals. Outlying GRAMMAR+ residuals 
(absolute z-score >4) were removed and the remainder rank-based inverse-normal 
transformed. (3) Genome-wide association testing was performed using REGSCAN v0.5106. 
 
Genome-wide association results were clumped by linkage disequilibrium using PLINK 
v1.90101,102. Biallelic variants within ±5Mb and r2 >0.2 to the lead variant (smallest p-value at 
the locus) were clumped together, and the lead variant is presented. r2 was derived from all 
European populations in 1,000 Genomes92,93. 
 
We have chosen to describe pQTL as local- or distant- so as to distinguish naming based on 
genomic location from that based on mode of action i.e. cis- (acting on the same DNA 
molecule) and trans- (acting via some diffusible mediator). That is, most local- variation may 
well act in cis but not necessarily so. 
 
Mendelian Randomisation. In the context of proteome-by-phenome MR, a DNA variant (a 
single nucleotide polymorphism in this case) that influences plasma protein level is 
described as an ‘instrumental variable’, the protein as the ‘exposure variable’, and the 
outcome phenotype as the ‘outcome variable’. 
The lead-SNP with the lowest p-value meeting the following criteria was used as the 
instrumental variable for each protein: 
(1) Minor allele frequency >1% in both ORCADES and CROATIA-Vis cohorts. 
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(2) An imputation info score (SNPTEST v2) of >0.95 in both ORCADES and CROATIA-Vis. 
(3) Located within ±150kb of the gene coding for the protein (start and end coordinates 
of the gene as defined by Ensembl GRCh37107). 
(4) Significant (as defined below) SNP:protein link in both the discovery and replication 
cohorts. 
 
Lead-SNP selection was performed using the discovery (CROATIA-Vis; p-value <5x10-8) 
cohort; replication was defined based on a Bonferroni correction for the number of 
significant lead-SNPs present in the discovery cohort (CROATIA-Vis). In order to avoid a 
‘winner’s curse’, genome-wide association effect size estimates and standard errors from 
the replication cohort (ORCADES) were used for MR.  
 
We perform MR as a ratio of expectations, using up to second-order partial derivatives of 







where βij is the causal effect of j on i, seij is the standard error of the causal effect estimate of 
j on i; subscript X is the exposure, Y the outcome trait, and Z the instrumental variable. Φ is 
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the cumulative density function of the standard normal distribution. This method is identical 
to that of SMR27 apart from the second term in the bracket of Equation 1 (resulting from the 
inclusion of second-order partial derivatives). An FDR of <0.05 was considered to be 
significant. FDR estimations were performed separately on those results derived from 
GeneAtlas and those derived from studies in Phenoscanner. 
 
DNA variant to trait association: GeneAtlas. UK Biobank has captured a wealth of 
information on a large – approximately 500,000 individuals – population cohort that includes 
anthropometry, haematological traits, and disease outcomes. All 778 outcome traits from 
UK Biobank in GeneAtlas (http://geneatlas.roslin.ed.ac.uk/; Canela-Xandri et al. (2018)10) 
were included. The analysis method of all 778 traits was as described for 717 in Canela-
Xandri et al. (2017)29. For each protein, the lead (lowest DNA variant-protein association p-
value in the discovery cohort) biallelic (Phase 3, 1,000 Genomes92,93) variant meeting the 
criteria above and an imputation info score >0.95 in UK Biobank, was selected for each 
protein, and MR performed. 
 
DNA variant to trait association: Phenoscanner. Phenoscanner67,68 was used to highlight 
existing GWA studies for inclusion. For each protein, the lead (lowest DNA variant-protein 
association p-value in the discovery cohort) biallelic (1,000 Genomes92,93) meeting the 
criteria above was selected. rs545634 was not found in the Phenoscanner database and was 
therefore replaced with the second most significant variant meeting the above criteria: 
chr1:15849003. Phenoscanner was run with the following options: Catalogue: ‘Diseases & 
Traits’, p-value cut-off: ‘1’, Proxies: ‘None’, Build ‘37’. The results from those studies that 
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returned a value for all input variants were kept and MR performed. Phenoscanner 
(http://www.phenoscanner.medschl.cam.ac.uk/information/; accessed 25 Sep 2018) state 
that they report all SNPs on the positive strand. Given this, alleles were harmonised as 
required. No attempt to harmonise based on allele frequency was made; therefore, the 
direction of effect of C/G and A/T SNPs should be interpreted with care. Results from 20 
additional studies were obtained, corresponding to 68 outcomes. 
 
HEIDI. Heterogeneity in dependent instruments (HEIDI) analysis27, is a method of testing 
whether the MR estimates obtained using variants in linkage disequilibrium with the lead 
variant are consistent with a single causal variant at a given locus (Figure 1d).  HEIDI analysis 
was performed using software provided at https://cnsgenomics.com/software/smr/ 
(accessed 28 Aug 2018; v0.710). We used pQTL data from ORCADES for assessment as the 
exposure. Biallelic variants from the 1,000 Genomes92,93 (European populations: CEU, FIN, 
GBR, IBS, and TSI) were used as the linkage disequilibrium reference. We used the default 
‘cis-window’ of 2000kb, and a maximum number of variants of 20 (as is the default value for 
the software). 
 
We performed HEIDI analysis of all exposure-outcome links that were found to be significant 
(FDR <0.05) using outcomes from GeneAtlas (n =271), as well as links found to be MR 




We applied the following filters for variants to be included in the analysis: minor allele 
frequency MAF >0.01 and, in the GeneAtlas and ORCADES data, an imputation info score of 
>0.95. 
 
Comparison to eQTL 
Result for all SNP:gene pairs analysed in whole blood were downloaded from GTEx13 (v7). 
Results were extracted for the instrumental variables and the genes encoding their proteins 
for the 64 proteins for which an instrumental variable was successfully identified in this 
study. Matching was based on Ensembl Gene ID, and variant chromosome, position, and 
alleles (GRCh37). 
 
Comparison to plasma pQTL using an orthogonal, aptamer-based, method 
The supplementary data files for Sun et al14 were downloaded on 04 Sep 2019. pQTL 
identified were extracted for the 64 proteins for which an instrumental variable was 
successfully identified in this study.  Proteins were matched based on an exact UniProtID 
match. The LD (r2) between the lead locally-acting (as defined above) and ‘cis-acting’ (as 
defined by Sun et al.) SNP identified for each protein was calculated using the European 





Links to existing drug therapies 
Protein names were matched to ChEMBL IDs using the UniProtID mapping API 
(https://www.uniprot.org/help/api_idmapping; accessed 27 Oct 2019). ChEMBL109 was 
searched programmatically using the ChEMBL web resource client in Python 3.6 
(https://github.com/chembl/chembl_webresource_client; accessed 27 Oct 2019). 
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Figure 1. Proteome-by-phenome Mendelian Randomisation. 
A) Genome-wide associations of the plasma concentrations of 249 proteins from two 
independent European cohorts (discovery and replication) were calculated. The plot shows 
pQTL position against chromosomal location of the gene that encodes the protein under 
study for all replicated pQTLs. The area of a filled circle is proportional to its -log10(p-
value) in the replication cohort. Blue circles indicate pQTLs ±150kb of the gene (‘local-
pQTLs’); red circles indicate pQTLs more than 150kb from the gene. B, C) Local-pQTLs of 64 
proteins were taken forward for proteome-by-phenome MR analysis. These were assessed 
against 778 outcome phenotypes from GeneAtlas29 (panel B; UK Biobank) and 68 
phenotypes identified using Phenoscanner67,68 (panel C). In each set of results an FDR of 
<0.05 was considered significant. D) Heterogeneity in dependent instruments (HEIDI27) 
testing was undertaken for MR significant results from GeneAtlas (n =271). This test seeks 
to distinguish a single causal variant at a locus effecting both exposure and outcome 
directly (as in i) or in a causal chain (as in ii), from two causal variants in linkage 





Figure 2. Significant (FDR <0.05) proteome-by-phenome MR protein-outcome causal inferences: disease subset. 
MR significant (FDR<5%) protein-disease outcome results.  
a) All MR significant (FDR<5%) protein-disease outcome results for outcomes from the 
Phenoscanner67,68 studies (see key for details).  
b) All MR significant (FDR<5%) protein-disease outcome results for outcomes from 
GeneAtlas29. An asterisk indicates MR estimates that are not significantly heterogeneous 
upon HEIDI testing (see key for details). 
c) Key. From the outside in: HGNC symbol of the protein (exposure); disease outcome; key 
colour (matching the protein name in the outer ring); bar chart of the signed squared beta 
estimate divided by the squared standard error of the MR estimate, using pQTL data from 
the discovery cohort (CROATIA-Vis); bar chart of the signed squared beta estimate divided 
by the squared standard error of the MR estimate, using pQTL data from the 
replication cohort (ORCADES). Central links join identical outcomes for which more than one 
protein was found to be MR significant. The colour of the links indicates similar outcome 
groups, e.g. thyroid disease. 
The key to the outcome descriptions is detailed further in Supplementary Table 8 and 
Supplementary Table 9. 
d) Example concordance (due to sample overlap) plot for all proteins with significant MR 
evidence in GeneAtlas for causal roles in asthma (IL1RL1, IL1RL2, IL2RA, IL4R, IL6R). 
GeneAtlas traits are on the left. Phenoscanner traits are on the right. Thickness of 
connecting lines is proportional to -log10(p-value). The Phenoscanner studies included here 
are derived from 47,49,50,53,61,64–66, of which 49,61,65,66 include at least some part of the UKBB 
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data. However, 49,65,66 use only data from the first phase (~150,000 individuals) genotype 




Figure 3: Co-localisation of SHPS1 (encoded by SHPS1: synonym SIRPA) and schizophrenia DNA associations. 
Upper panel, locuszoom110 of the region surrounding  SHPS1 and the associations with 
schizophrenia51; lower panel, associations with SHPS1. Lower panel inset, the relative 
concentration of SHPS1 across the 3 genotypes of rs4813319 – the DNA variant used as the 






3. Cellular mass-spectrometry based proteomics 
Introduction 
Peripheral blood mononuclear cells (PBMCs) are a site of active gene expression in blood 111. 
Recent endeavours have begun to unravel the depths of the human proteome and have 
found many genetic variants influencing protein abundance. If one is happy to accept that 
protein abundance cannot influence genotype of an individual, then these are causal links. 
However, due to the relative ease of sampling, previous studies have generally focused on 
plasma proteomes 14,41–43, or model cellular systems (such as induced pluripotent stem cells 
19). Unfortunately, plasma protein abundance derives from multiple sources and is unlikely 
to be representative of any single cell-type or tissue, and it remains an open question as to 
how representative the plasma proteome is of any primary tissue. 
 
PBMCs, composed of lymphocytes and other mononuclear cells (natural killer cells, 
dendritic cells, and monocytes), play a central role in the human immune-system. They are 
instrumental in both the pathogenesis and prevention of many important diseases. They are 
deeply entwined in the genesis of auto-immune disease, and are directly involved in the 
host-response to infection. In addition, they are also the target tissue of many globally 
important diseases, especially viral infections, including human immuno-deficiency virus 
(HIV), Epstein-Barr virus (EBV), and human T-cell lymphotropic virus (HTLV). PBMCs 
therefore represent an important physiologically relevant tissue – the proteome of which I 
have assessed directly, and at scale. 
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The difficulty with traditional measurements of protein abundance, for example western 
blotting, is that they are not easily scalable. Current technologies used to assess the 
proteome at population scales can broadly be categorised into two groups: antibody-based 
assays, and aptamer-based assays. As the name implied, antibody-based assays, such as the 
Olink platform (as used in Chapter 2), use one or more antibodies targeted at the proteins 
of interest. In the case of the Olink platforms, the array has a matched pair of antibodies for 
each protein, each linked to one of a pair of oligonucleotides. Binding of both the antibodies 
to the protein brings the paired oligonucleotides into close proximity. This permits 
hybridization, and these oligonucleotides then form the basis of a quantitative PCR reaction. 
This then allows relative quantification (between samples) of protein abundance 105. 
As with the Olink assays, aptamer-based assays aim not to measure protein abundance 
directly, but to measure DNA abundance as a proxy. ‘Slow off-rate modified aptamer’ 
(SOMAmer) technology 112 involves oligonucleotide aptamers with protein-like side-chains 
that binds to a target molecule (in this context a protein). These are available commercially 
as part of an aptamer-based multiplex protein assay (SOMAscan) and has been used to form 
the basis of the largest analysis of the human plasma proteome to date 14. However, whilst 
these technologies are useful, they are not a panacea. Specificity to their putative targets, 
especially in complex mixtures, is difficult to guarantee. Interestingly, in order to assess the 
binding specificity, academia and industry often recourse to mass-spectrometry based 
methods 113. 
 
In this chapter I present, a direct assessment of the cellular proteome of PBMCs with high-
performance liquid chromatograph mass-spectrometry (HPLC-MS/MS). This enables a 
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deeper assessment of the proteome than is possible with current antibody-, or aptamer-
based technologies, and is not affected by the difficulties of binding-specificity. 
 
Here I present the first phase of a much larger study, demonstrating the feasibility of 
assessing the cellular proteome of PBMCs, using HPLC-MS/MS, at a population scale. I 
describe the results of the first 251 samples processed. Even at this scale, this is, to the best 
of my knowledge, the first study to systematically assess paired genomic and proteomic 
information to this depth, at a population-scale, in primary human cells. 
 
Currently the results include assessment of the genome-wide association of 4,433 proteins, 
each measured in 100 or more samples of PBMCs from 251 individuals. In addition, the 
number of proteins, and the proportion of samples within which they are detected, is 
expected to improve as the project progresses. 
 
In this chapter, I perform GWA of the 4,433 proteins and assess concordance with eQTL and 
plasma pQTL, using results from GTEx 13 and Sun et al. 14, respectively. Finally, rheumatoid 
arthritis was selected as a representative autoimmune disease – a group of diseases for 
which PBMCs are likely a relevant set of cell-types – and two-sample Mendelian 




The PBMC samples for the main part of this study were obtained from Generation Scotland 
(GS application number for this project: GS18318). Generation Scotland: Scottish Family 
Health Study (GS) is a population- and family-based cohort from the Scottish population. 
Participants were recruited between 2006 and 2011 and blood samples obtained at the time 
of recruitment. The cohort has previously been described in detail elsewhere 114. 
Participants provided written informed consent. Ethical approval was provided by the East 
of Scotland Research Ethics Service committee on research ethics (REC references 
15/ES/0040). 
 
Peripheral-blood mononuclear cell preparation 
PBMC samples were available for 862 genotyped individuals from Generation Scotland. 
PBMCs were separated from approximately 5ml blood in acid-citrate-dextrose using density 
gradient separation (Histopaque-1077; Sigma-Aldrich) by the European Collection of 
Authenticated Cell Cultures (ECACC) using a standardised protocol. PBMCs were frozen in a 
rate-controlled manner and stored in liquid nitrogen (in foetal-calf serum with 10% DMSO) 
until withdrawn for this study. In addition, further PBMC samples were obtained for 
protocol optimisation, using an analogous extraction technique to that used in Generation 
Scotland, at the Roslin Institute, ethical approval for which was granted by South East 




Genotyping and downstream processing of genotypes had already been performed prior to 
the commencement of this study. In brief, it was performed at the Genetics Core Laboratory 
at the Clinical Research Facility, University of Edinburgh, Scotland using the 
HumanOmniExpressExome-8 v1.0 or v1.2 BeadChips with Infinium chemistry (Illumina). 
Genotypes were processed using the GenomeStudio Analysis software v2011.1 (Illumina) 
and called using Beadstudio-Gencall v3.0 (Illumina). The details of blood collection and DNA 
extraction are provided elsewhere 115. Quality control: individuals with <98% call rate, SNPs 
with <98% call rate, or a Hardy-Weinberg equilibrium p-value <1x10-6. The resulting data set 
was merged with data from the 1000 Genomes project 116 and a principal component 
analysis performed using GCTA 117. Individuals more than six standard deviations away from 
the mean of principal component 1 and principal component 2 were removed. SNPs with a 
minor allele frequency <0.05 were removed. Following this, 519,798 genotyped autosomal 
SNPs remained. 
 
Sample preparation for mass-spectrometry 
The MRC Institute of Genetics and Molecular Medicine (IGMM) mass-spectrometry team 
already had protocols for sample preparation for mass-spectrometry for small numbers of 
samples. In collaboration with them, I undertook optimisation of their existent protocols to 
ensure the practicality of performing this in a standardised way, at scale. Initial data were 
obtained using the samples from the Roslin Institute, and subsequently using ungenotyped 
samples from Generation Scotland. Protocols were followed, as closely as was practical, 
with the following notable exceptions: 1) The pooled standard and Batch 1 were originally 
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sonicated with a BioRuptor for 20 min. However, during the processing of Batch 1, this was 
found to be ineffective at fully disrupting the nucleic acid. Each sample from Batch 1 was 
therefore further sonicated using a Soniprep 150 for 10sec at 5µm amplitude. As reflected 
in the protocol, the Soniprep 150 was then used as the principal method for subsequent 
batches; 2) Batch 4 received an additional wash with 10ml phosphate buffered saline per 
sample; and 3) The digest of batches 1-3, and 6 were repeated using frozen cell lysate rather 
than directly from cell lysate on dry ice. The final protocols are found in the supplementary 
materials, and are summarised below. 
Cell preparation and lysis 
Frozen cell pellets were retrieved from liquid nitrogen and washed three times in chilled 
phosphate buffered saline (once with 9ml, twice with 10ml) prior to lysis in 40µl of 6M 
guanidine hydrochloride with 100mM tris(hydroxymethyl)aminomethane (tris) – ‘lysis 
buffer’. 2µl of sample was taken for a protein assay (Pierce BCA protein assay, Thermo-
Fisher; Catalog number 23227). Based on the results of this assay, protein concentrations 
were standardised to a ceiling of 15µg of protein per well of a 96-well PCR plate in 20µl of 
lysis buffer. Following lysis, samples were sonicated to ensure disruption of nucleic acid. In 
addition to the samples of the batch, per-plate, an additional within-batch repeat and up to 
two between-batch repeats were included. Samples were prepared in batches: 19 batches 
of 43, and one of 45. 
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Protein digest and peptide preparation 
Each sample was reduced with tris-carboxyethylphosphine (TCEP; 1µl 100mM), alkylated 
with chloroacetamide (CAA; 1µl 200mM), and heated for 5 minutes to 90-95°C. After 
cooling, samples were diluted two-fold with 20µl 100mM tris (pH 8.5) and digested 
overnight with mass-spectrometry grade lysyl endopeptidase (300µg per well. Wako: 
reference 121-05063; lot numbers CAR3124 and CAR3125) at 37°C. Samples were then 
diluted a further three-fold with 80µl 50mM tris (pH 8.5) and digested for 4 hours with 
trypsin (150µg per well; Pierce (Thermo Fisher) reference 90058, lot TG269839), again at 
37°C. Digestion was stopped by the addition of 16µl 10% trifluoroacetic acid (TFA) per well. 
Peptides were de-salted on C18 columns 118,119. Columns were activated with 15µl 
methanol, washed with 50µl 0.1% TFA (pre- and post- sample loading), and eluted with 40µl 
80% acetonitrile (ACN) + 0.1% TFA. Following elution, samples were dried and resuspended 
in 14µl mass-spectrometry grade water. 5µl of each sample was taken for a peptide assay 
(Pierce Quantitative Colorimetric Peptide Assay (Thermo Fisher) Catalog number 23275). 
The remaining 9µl of sample were acidified with 1µl 1% TFA and stored frozen prior to mass-
spectrometry analysis. 
 
Pooled standard and library generation. 
A pool was generated from 20 individuals from GS. The pool was aliquoted into 20µl 
aliquots (containing 15µg protein per aliquot) and prepared as the primary samples. 
However, following resuspension in water, the samples were again pooled. The pool was 
then split: part for use as a pooled standard for running with each batch, and part for the 
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genesis of a peptide library. 20µl of the pooled standard was run with each batch. Note that 
the peptide library was not included in the results of the first phase analysis presented here. 
 
Mass-spectrometry machine protocol 
LC-MS/MS was performed on a Thermo Ultimate 3000 RSLC Nano UPLC coupled to a 
Thermo Fisher Q Exactive plus mass-spectrometer (Thermo Fisher). Samples were directly 
injected from a 96-well plate onto an Aurora UHPLC column from IonOpticks (Ion Opticks 
Pty Ltd). A Proxeon nano-spray ionisation source (Proxeon Biosystems) with a capillary 
temperature of 250°C and an optimised voltage of 1.4-1.7kV was used. A 120 minute 
gradient (2%-30% B in 110 min, 30-45%B in the next 10 min; A=2% acetonitrile, B=80% 
acetonitrile, 0.5% acetic acid throughout; the composition was raised to 100% B in 7 
minutes after the analytical gradient to wash the column, and total equilibration time was 
20 minutes), data-dependent acquisition, was run with a scan range of 350 to 1400 m/z   
using the Orbitrap at a resolution of 70,000 in profile mode. The top 24 parent peaks were 
selected for fragmentation. HCD fragmentation was performed with a normalised collision 
energy of 26 and spectra were acquired in centroid mode at a resolution of 17,500. Charge-





Data search and annotation. 
Data were processed using MaxQuant 33,34 (v1.6.5.0), matching against UniProt human 
(9606) reference proteome (5640) release 2019_01 120 The search was performed for 
trypsin-digested peptides with up to two permitted missed cleavages, the fixed modification 
carbamidomethylation (C), and the variable modifications of oxidation (M) and acetylation 
(Protein N-terminus). MaxQuant match-between-runs and label-free quantification were 
used 121. The false discovery rate of the peptide-spectrum matches was calculated using a 
decoy-target approach. A threshold of 0.01 used for the search. Match between run 
parameters: matching time window: 0.7 minutes; alignment time window: 20 minutes. 
Data transformation 
Label-free quantification (LFQ) values were quantile-normal transformed per sample. 
Missing data were imputed into the lower tail of the normal distribution. Proteins that were 
measured in fewer than 100 samples were not included in further analysis. 
Genome-wide association 
A linear mixed model was fit using GEMMA 122, for each SNP the phenotype was fit against a 
model containing the SNP, an intercept, other fixed effects (age, age2, sex, batch, and 
haemoglobin subunit alpha abundance), and a standardized whole-genome genomic 
relationship matrix as a random effect. 
 
An initial genome-wide screen was performed as well as a subsequent local-pQTL analysis 
limited to ±1Mb window surrounding the gene start and end positions (as defined by 
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Ensembl GRCh37 107). I considered genotyped SNPs with a minor allele frequency >0.05 in 
the set of 251 individuals. A false discovery rate of <0.05 was considered to be significant in 
the locally- acting set. 
 
Mapping to GTEx (v6p) and plasma pQTL 
All per gene significant (as defined by GTEx) locally- acting (±1Mb from the transcription 
start site) eQTL in GTEx (v6p) 13 were searched for the lead-SNP of each significant (FDR 
<0.05) locally- acting (as defined above) pQTL identified in this chapter. Matches were based 
on chromosome, position, and alleles and ENSG ID. 
 
The supplementary tables of Sun et al. 14 were downloaded from the publisher’s website. 
Proteins were matched between the PBMC proteomics data and Sun et al. based on an 
exact UniProt ID match. 
 
Rheumatoid Arthritis Mendelian randomisation 
The full summary statistics of Okada et al. 53 (trans-ethnic) were searched for all the lead-
SNP of each significant (FDR <0.05) locally- acting (as defined above) pQTL identified in this 
chapter. Matches were based on rsID. Attempted replication of those SNPs significantly 
associated (Bonferroni correction) with rheumatoid arthritis (RA) in Okada et al. was 
attempted in the GeneAtlas 10, and consistency of causal effect of protein on disease 





















bSNP:RA and bSNP:PROT are the effect estimates of the SNP on rheumatoid arthritis, and protein 
abundance respectively. 
sSNP:RA and  sSNP:PROT are the standard errors of the effect estimate of the SNP on rheumatoid 
arthritis and the protein abundance respectively. 
 
Results 
I identified 4,433 proteins in PBMCs, each in 100 or more samples, at a peptide-spectrum 
match false-discovery rate of <0.01. At a genome-wide significance threshold (Bonferroni 
threshold; p-value < 5x10-8/4,433), I identified 25 proteins with one or more pQTL. Of these, 
21 mapped to an autosome (Ensembl GRCh37 107) and, in all 21 instances, were located 
within 1Mb of a gene encoding the protein. When focussed on local variation (±1Mb of the 
mapped gene(s) encoding the protein under study), I identify 108 proteins with one or more 
significant (false discovery rate (FDR) <0.05) pQTL. These 108 proteins map to 113 Ensembl 
	62	
Gene IDs (GRCh37) 107. Of these, the SNP:ENSG ID pair was also called a significant per ENSG 
ID expression quantitative trait locus (eQTL) in whole blood from GTEx (v6p) 13 in 38.1% 
(43/113; Supplementary Table 10), with a consistent direction of effect in 92.7% (38/41; 
Figure 3.1; C/G and T/A SNPs excluded from directional concordance analysis). The co-
efficient of determination of the linear trend line was 0.45, broadly similar with estimates 
from previous studies 19. 
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Figure 3.1: Comparison of peripheral blood mononuclear cell pQTL and whole blood eQTL. 
Beta estimates from peripheral blood mononuclear cells pQTL (FDR <0.05, locally- acting, 





Rheumatoid arthritis is an inflammatory arthropathy affecting approximately 1% of the 
worlds’ population. It is not only a destructive joint disease, but can also have serious 
systemic effects, for example interstitial lung disease. Given the inflammatory nature of this 
globally important condition, it was felt to be a good test case for MR using immune-cell 
specific protein pQTLs. 
 
The 108 significant (FDR <0.05) locally- acting PBMC pQTL lead-SNPs were looked up in the 
results of a large rheumatoid arthritis (RA) genome-wide association (GWA) study 53. Of 
these, 104 were reported in the outcome study, and 7 SNPs were found to be significant 
(Bonferroni correction, p-value <0.05/104), corresponding to the pQTL of HLA-DQA1, NELFE, 
PADI4, HLA-B, RNASET2, PADI2, and HLA-F. Of these, two of the SNP:RA associations (the 
SNPs tagging PADI2 and HLA-F) were not genome-wide significant (p-value >5x10-8) in the 
RA GWA results. 
 
The SNPs tagging HLA-DQA1, NELFE, and PADI4 all replicated (Bonferroni correction, 0.05/7; 
associated with rheumatoid arthritis (ICD10: M05 Seropositive rheumatoid arthritis) and a 
consistent direction of effect) in GeneAtlas 10 (p-values: 6.65x10-12, 1.15x10-8, and 3.23x10-3, 
respectively). Interestingly PADI2 and PADI4 are both (and the only) members of the 
‘histone H3-R26 citrullination’ pathway (GO:0036413). Citrullination of proteins being a key 
feature of the pathogenesis of RA, indeed, anti-cyclic citrullinated peptide (CCP) antibodies 
are used in clinical practice as part of the diagnostic work-up for RA, and are often 
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detectable in the blood many years before the development of RA 123. The lead-SNP for 
PADI2, rs2235910, is genome-wide significant in PBMCs (p-value 6.88x10-13), corroborated 
by GTEx (v6p 13; p-value 2.82x10-101); the lead-SNP for PADI4, rs2240335, is an FDR <0.05 
locally- acting pQTL in PBMCs (p-value 1.40x10-5) but is not a significant eQTL in whole 
blood. However, it is a significant eQTL – minimum p-value 7.55x10-21 – in other 
(predominantly brain) tissues in GTEx (v6p) 13, thus demonstrating the benefit of measuring 
cellular protein abundance. 
 
Increased enzymatic activity of PADI2 and PADI4 have previously been found in the synovial 
fluid of rheumatoid arthritis patients 124,125. MR demonstrates that increased mean protein 
level is associated with increased risk of RA for both PADI2 and PADI4 (Table 3.1), leading 
one to the conclusion that increases in mean PADI2 and PADI4 abundance causally 
contribute to rheumatoid arthritis. Consistent with this, there have been recent successes in 
the use of PADI-inhibitors for the treatment of mouse models of rheumatoid arthritis (pan-
PADI inhibition 126,127;  PADI4 128). Indeed, the pan-PADI inhibitor BB-Cl-amidine has even 
been shown to reverse immune-mediated joint inflammation 127. It is currently thought that 
the association of PADI enzymes and RA is broader than simply generating citrullinated 
epitopes 128. PAD4 has previously been shown to affect gene transcription via regulation of 
the balance between histone arginine methylation and citrullination 129 and, it has 
previously been shown that PADI2 is also able to translocate to the nucleus and regulate the 
citrullination of histone H3 130. 
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With respect to the other proteins identified as causally contributing to RA (Table 3.1), there 
is significant pre-existing literature linking HLA subtypes and the extended major 
histocompatibility complex (MHC) region with RA 131–137. However, given the strong LD 
within the region, pleiotropy must be considered carefully when interpreting these results. 
Finally, RNASET2 has previously been identified as an ethnicity specific (‘Asian-specific’) RA-
associated gene 138. 
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Table 3.1: Mendelian Randomisation (MR) estimates of the effect of protein on rheumatoid arthritis 
SNP:protein estimates from PBMCs, SNP:RA estimate from Okada et al. 53. A positive b 
estimate implies that increasing mean protein concentration increases risk of developing 
rheumatoid arthritis. MAF: Minor allele frequency from the PBMC pQTL results. 
 
Protein bMR estimate Standard errorMR MR p-value MAF 
HLA-DQA1 -1.33 0.23 1.67x10-8 0.249 
NELFE 0.89 0.19 4.93x10-6 0.263 
PADI4 1.22 0.31 7.74x10-5 0.317 
HLA-B 0.93 0.23 4.47x10-5 0.076 
RNASET2 -0.80 0.16 9.85x10-7 0.464 
PADI2 0.44 0.10 1.26x10-5 0.351 




Which PADI? The benefits of breadth. 
All known PADI enzymes (PADI 1,2,3,4, and 6) are located in a cluster on human 
chromosome 1 (Figure 3.2). An assumption of MR is that the SNP (instrumental variable) 
does not affect the outcome, except via the protein (exposure) itself; or put another way, 
that the SNP has no horizontal pleiotropy. One benefit of a study of great breadth is that 
one can directly test this assumption. For example, I have directly measured 3 of the 5 PADI 
enzymes and, notwithstanding arguments about statistical power, am able to conclude the 
following: the lead-SNP for PADI2 (rs2235910) is not significantly associated with PADI4 
abundance (p-value 0.41), nor was the lead-SNP for PADI4 (rs2240335) significantly 
associated with PADI2 (p-value 0.66); neither SNP was associated with PADI3 abundance (p-
values 0.14 and 0.81, respectively). 
 
Transcription of a genomic region is correlated with the degree to which the DNA CpG sites 
are methylated. I hypothesised that if a SNP was affecting protein abundance, i.e. it is a 
pQTL, that it may also be a meQTL for some (or all) of the CpGs across the gene encoding 
that protein. However, the expected direction of causation is not necessarily clear. I 
undertook to assess this for PADI2 and PADI4 and present initial encouraging results (Figure 
3.2). Obviously, this is a result that will require confirmation and generalisation, however, in 
these two cases, it is striking. In the case of PADI2, there is an almost exclusive relationship 
between meQTL significance and physical location within the gene, and in the case of PADI4, 
almost so. The peak of the PADI4 lead-SNP is slightly broader, and not as tall, this is 
concordant with the lower beta estimate and less significant p-value of the SNP:protein 
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association (rs2235910:PADI2 in PBMCs, b estimate 0.19, p-value 6.88x10-13; 
rs2240335:PADI4 in PBMCs, b estimate 0.11, p-value 1.40x10-5). 
 
This may represent an efficient way of assessing the pleiotropic effects of a SNP in MR 
studies of the future. For example, if one were to assess the effect on methylation of the 
lead-SNP of a known pQTL across the genome, then one might expect a peak of meQTL hits 
over the gene encoding the protein for which it is a pQTL. However, there may also be other 
peaks which may represent the pleiotropic effects of the SNP (horizontal or vertical). Also, 




Figure 3.2: Effects of PADI2 and PADI4 pQTL SNPs on CpG methylation 
Locus zoom 110 plots of all meQTL (Methods) with an association p-value <1x10-3 between 
the SNP and the CpG. Points on this plot are individual CpG sites. The significance reported 
is the association of the model SNP:CpG association (as described in Chapter 4). Note, the 
set of CpG potentially included in each graph is the same. Each plot is centred on the gene 
encoding the protein for which the SNP is a pQTL with a 1Mb flank. The purple diamond 
represents the position of the lead-SNP of the pQTL: its position on the y-axis is not 
meaningful. Shading is a visual aid to mark the gene of interests in the centre of the plot. 
A) meQTL associations of lead-SNP for PADI2 (rs2235910). As can be seen the lead 
PADI2 SNP is associated with CpG methylation changes across the PADI2 gene, with 
no such enrichment over the PADI1, 3, 4, or 6. 
B) meQTL associations of lead-SNP for PADI4 (rs2240335). The lead PADI4 SNP has a 
broader, less significantly associated, peak: concordant with its lower beta estimate 








Comparison with plasma pQTL 
In one of the largest pQTL studies to date, Sun et al. 14 evaluated the plasma proteome to 
previously unprecedented depth. They assessed 3,608 unique UniProt IDs, of which 1,245 
overlap with those assessed in this study. That is, 2,363 UniProtIDs are unique to Sun et al., 
and 3,734 unique to this study. At first glance, one may be surprised by the degree of 
overlap observed. However, it is worth noting that protein inclusion in this study is data 
dependent – that is, the MS features chosen to fragment (and thus attempt identification) 
are defined by the peptide content of the sample itself – whereas the proteins included by 
Sun et al. are those chosen a priori for inclusion on the panel by SomaLogic. 
 
Neither PADI2, nor PADI4 were assayed in the plasma proteome of Sun et al. 14. Of the 108 
significant (FDR <0.05) locally- acting pQTL identified in this study, 37 of the Uniprot IDs 
were assessed in Sun et al., and of those, 16 were reported as having a locally- acting pQTL 
(within ±1Mb of the transcription start site of the corresponding protein-coding gene). 
Interestingly, for those UniprotIDs where both studies reported a significant (FDR <0.05 
here; p-value <1.5x10−11 Sun et al.) locally- acting pQTL, the linkage disequilibrium (r2) 
between the lead-SNPs was >0.8 in only 50% (8/16) of cases (13 r2 values reported: mean 
0.50; range 1.21x10-3 to 1.0; values 0.00, 0.00, 0.01, 0.01, 0.09, 0.12, 0.68, 0.81, 0.92, 0.93, 
0.95, 0.97, 1.00. Lead-SNP identical in 2 cases. 1 pair not assessed as SNP flagged as 
multiallelic in the LD reference). This disparity may be due to a number of reasons: 1) the 
SNP density of our genotyped SNPs when compared to the imputed data of Sun et al. may 
necessitate the use of poor genetic proxies, 2) there may be technical issues with the 
protein specificity of either of the assays, or 3) there may be truly different molecular 
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mechanisms underlying the protein abundance change observed in each study. For 
example, one SNP may increase the rate of intra-cellular breakdown of a protein, without 
affecting the amount excreted by the cell, or the effects of a SNP may by context 
dependent, and only affect protein concentration in PBMCs with the effect on plasma 
abundance as a whole being negligible. Therefore, there is clear virtue in the assessment of 
cellular proteomes and one should not simply rely on studies of plasma proteins alone to 
evaluate the genetic control of the proteome in general terms. 
 
Discussion 
Here I have presented the results of 251 peripheral blood mononuclear cell samples; 
representing the first phase of 861 currently being processed. I have examined the genetic 
associations of 4,433 (FDR <0.01) proteins, each measured in the peripheral blood 
mononuclear cells of 100, or more, samples. Already, this is the largest population-level 
study of the cellular proteome to date. Indeed, it is also the deepest assessment of the 
peripheral blood mononuclear cell proteome to date 111. 
 
Protein, not RNA, is key for drug discovery 
eQTL are of great interest and their ease of measurement has made them an attractive early 
route through which to annotate the pathway between genotype and disease. Based on 
data from the GTEx project, nearly 50% of common genetic variants were found to be 
associated with gene expression 13,139. Unfortunately, without careful interpretation, this 
apparent success can easily lead to false conclusions regarding the consequences of a given 
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genetic variant. A SNP, or variants in linkage disequilibrium with it, may affect more than 
one gene (horizontal pleiotropy), and regulation can occur at all levels of protein 
production. In addition to this, previous studies have shown pQTLs are enriched for disease 
linked variation when compared to eQTLs 19. When comparing the correlation of beta 
estimates of our PBMC pQTLs with the eQTLs of whole blood from GTEx (v6p) 13, with a co-
efficient of determination of 0.45, our results are broadly consistent, with those of previous 
studies 19. The biological component contributing to the imperfect correlation between RNA 
and protein abundance may have important consequences, especially for drug discovery, as 
the molecular targets of most drugs in use today target protein, not RNA. 
 
Comparison to plasma proteomes and other technologies 
The distinction between the cellular and the extra-cellular proteome profile is an important 
one. The true source of many of the proteins contained within the plasma is far from clear. 
The plasma proteome represents a composite measure of many cell-types and tissues. I find 
an incomplete overlap between the lead-SNPs for approximately half of the proteins for 
which a significant (FDR <0.05 PBMC pQTL; p-value <1.5x10-11 plasma pQTL) exists in both 
PBMCs and plasma. The potential reasons for this are multitudinous. Ranging from 
proteolytic cleavage of cell-surface receptors 94, through to epitope changes for both 
antibody and aptamer-based technologies.  
 
One potential pitfall of using mass-spectrometry based assessment of protein abundance is 
the difficulty in mapping ‘features’ to peptides. A mass-spectrometry proteomics ‘feature’ is 
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a species that elutes off the column at a specific time with a specific m/z profile. The 
protocol used to prepare the samples for mass-spectrometry is designed so that each of 
these features represents a peptide from the digest of the sample. However, whilst all the 
features (when present) are measured in all the samples, without MS2 fragmentation of the 
feature, it is not clear which peptide a particular feature represents. However, the 
identification of features in one sample carries to other samples (i.e. ‘match-between-
runs’), and so the more samples run (i.e. the more MS2 spectra acquired) and the use of a 
high-pH, reversed-phase, peptide library greatly increases the number of features identified 
per sample. A high-pH reversed-phase peptide library is designed to separate peptides by 
hydrophobicity in an orthogonal manner to the low-pH reversed-phase gradients used as 
part of the LC-MS/MS setup. Not only this, some of the additional peptides identified are 
likely to derive from previously unidentified proteins, and so, as more features are 
identified, the depth to which the proteome is covered will also increase. 
 
As is standard in the mass-spectrometry proteomics field, in this study I used a database 
method involving in silico protein digestion. Non-synonymous, or splicing changes are not 
represented in the database, leading to spuriously low values for proteins for which this is 
an issue. Future work focussing on the features themselves, peptides directly, or a mutation 
/ splice variant aware search are all potential solutions to this problem. However, in spirit, 
this issue is not dissimilar to that of altered epitopes (due to any non-synonymous variant 
that changes the conformation of the protein in such a way as to change the epitope) that 
plagues antibody and aptamer-based assays, as mentioned above. Notwithstanding the 
above discussion regarding the advantages of pQTLs over eQTLs for drug discovery, the 
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observed overlap of our results with eQTLs from GTEx (v6p) 13 – identified through an 
orthologous method – does provide a degree of confidence in the pQTLs presented here. In 
mass-spectrometry based proteomics, as peptide (and hence protein) identification is based 
on the HPLC elution and m/z profile of a feature, mass-spectrometry proteomics is not 
limited to a set of proteins that has been arbitrarily chosen to appear on an assay, but by 
the resolution of the HPLC and mass spectrometer themselves. The breadth of coverage of 
the proteome, and the post-translational modifications of such, by mass-spectrometry 
proteomic methods is truly spectacular. It enables a more thorough assessment of the 
effects of a variant on all the genes encoding proteins within a genomic locus than has ever 
been possible before. 
 
Rheumatoid arthritis 
I report significant MR links between PADI2 and PADI4 with RA, as well as other previously 
documented results. PADI inhibitors have shown great promise in the prophylaxis and 
treatment of RA models in mice 126–128. In addition, I demonstrate a link between a pQTL and 
the meQTL overlaying the gene of the protein under study (Figure 3.2). How ubiquitous this 
relationship is, and whether it extends to distantly- acting pQTL remains to be seen, and is 
an area of potential future work. However, it does present the exciting possibility of 




First and foremost, data collection of the remaining 610 samples needs to be completed, 
this is due to be completed by November 2019. Following the acquisition of the data, it will 
require to be searched. At which point, the analyses above will need to be redone. The 
difficulty of the peptide search and these analyses should not be underestimated. Potential 
difficulties include the computational resources required to perform a peptide search on 
681 samples plus a peptide library. At present we have fit the mixed model, with the SNP, in 
one go. This may not be practical when the sample size is increased 3.4-fold, the number of 
proteins identified increases by approximately 50%, and imputed genotype data is used. 
Once data acquisition is complete, full assessment of the correlation structure of the 
proteins identified per individual and the identification of outliers should be considered. 
Other potential improvements to the analysis include the investigation of other potential 
protein / peptide imputation strategies, for example, k-nearest neighbours’ imputation, and 
the analysis of unique peptides only. In the present analysis, we co-vary only for 
haemoglobin concentration, as a proxy for the degree of erythrocyte contamination in the 
sample. However, in the fullness of time it is likely to become possible to co-vary for a 
number of other cell-types by including more cell-surface receptors as proxies. In this way it 
would be possible to compensate for heterogeneity introduced between samples because 
of cell-type composition differences. When the analysis is run using a larger sample size, and 
the GWA run using imputed data, standard heterogeneity testing, for example HEIDI testing 
27, as discussed in Chapter 2, is likely to become useful. However, the investigation of the 




When using HPLC-MS/MS data, it is worth mentally separating the analysis into two 
compartments, that of the associations of HPLC-MS/MS features, for example SNPs and 
disease, and that of the identification of the features themselves. There is no theoretical 
reason, other than burden of multiple testing, not to perform a GWA on each of the 
features detected, with the perspective of identifying the molecule underlying the feature in 
a subsequent – targeted – HPLC-MS/MS study. This analysis method would also have the 
secondary benefit of blinding the researcher to the exposure variable, thereby removing a 
potential source of bias. 
 
Conclusions 
In this exploratory analysis, I have clearly demonstrated the feasibility of assessing the 
cellular proteome of peripheral blood mononuclear cells. I present the result of the first 251 
samples, of a total of 861 due to be processed. The sample preparation of the 861 has been 
completed and data acquisition of the remaining 610 is currently underway. However, I 
have already obtained the most in-depth profile of the proteome of peripheral blood mono-
nuclear cells ever completed. As sample size increases, and with the inclusion of a high pH 
reversed-phase peptide library, the number of peptides and proteins identified will only 
increase. The large increase in sample size will also enable far more nuanced analyses, 
including, but not limited to, the assessment of post-translational modifications. 
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4. DNA CpG methylation 
Introduction 
Cytosine methylation of DNA is an important epigenetic modification in Eukaryotes and, 
when disturbed, has been associated with the pathogenesis of numerous diseases 12,20,21. In 
molecular terms, it is the covalent addition of a methyl group to the DNA base cytosine, 
resulting in 5-methylcytosine. In humans, this mark predominantly occurs at CpG 
dinucleotides and, outside of CpG islands (where the situation is more complex), is wide-
spread across the genome 23. 
 
The degree to which a given CpG site is methylated (across a population of cells, and 
between individuals) can be under genetic control. Genetic sequence variation, and the 
surrounding variants in linkage disequilibrium with it, that lead to alteration of the 
methylation status of a particular CpG are termed a methylation quantitative trait locus, or 
meQTL. These can be local to the genomic location of the CpG site itself, or distant to it. 
Throughout this chapter, when describing the results I generated (unless explicitly stated 
otherwise) I will use ‘inter-chromosomal’ exclusively to describe the situation where the SNP 
and CpG are located on different chromosomes, ‘locally- acting’ when the SNP:CpG pair are 
located within 1Mb of each other (on the same chromosome), and ‘unconstrained’ where 
neither such restriction had been applied. 
 
The specific molecular mechanisms that enable a genetic sequence variant to influence DNA 
CpG methylation are not well understood. At certain genomic loci, CpG methylation is a 
	80	
dynamic process and is associated with a number of key factors. These include variable 
transcription factor binding and transcription of a region, as well as changes to the local 
chromatin state 23. It has previously been shown that the affinity of transcription factors for 
DNA can be both sequence and methylation dependent 140,141. The links between 
transcription factor binding-site occupancy, transcription, and epigenetic changes (including 
both CpG methylation and chromatin modification) are extremely complex 142,143 and are 
currently only partially understood. 
 
As with the prevalence of CpG methylation, transcription factor occupancy at transcription 
factor binding sites can also be under local and distant genetic control. A systematic 
difference in the mode of inheritance between genetic variation cis- and trans- 
(distinguished based on allele specificity) to transcription factor binding sites on 
transcription factor occupancy has recently been shown (in mouse livers) for three 
transcription factors: FOXA1, CEBPA, and HNF4A 143. They found that genetic variation cis- to 
transcription factor binding sites was more likely to demonstrate an additive mode of 
inheritance, whereas genetic variation trans- to transcription factor binding sites was more 
likely to exert dominance control. 
 
In addition to the differences in the mode of inheritance of cis- and trans- to transcription 
factor binding sites, there is a known enrichment of meQTL target CpG sites in upstream 
and 5ʹ untranslated regions 12, suggesting a relationship between variable methylation and 
regulatory control of transcription. Given this evidence, and the intimate link between 
methylation and transcription factor binding site occupancy 144, I hypothesised that variable 
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DNA CpG methylation in the binding sites of many human transcription factors may be 
under dominance genetic control. Transcription factors are the canonical trans- acting 
factors, and I therefore focused the majority of this chapter on a confident subset of trans- 
acting meQTL: inter-chromosomal meQTL. 
 
Mendelian dominance describes the situation where a recessive allele is masked by a 
dominant one, that is, a heterozygote will express the phenotype of the dominant allele 
over the recessive one. To put this another way, dominance can be thought of as the 
deviation of the heterozygote phenotype from the midpoint of the phenotype of the two 
homozygotes. Dominance is frequently seen in single gene disorders, for example, myotonic 
dystrophy, Huntington’s disease, and Marfan's syndrome 145. However, for ‘complex’ traits, 
classical GWA studies have focussed on estimated allelic effects rather than attempting to 
delineate additive and dominance genetic effects on trait value. Using this model, these 
studies have been remarkably successful in finding disease associated variants. However, 
both additive and dominance components contribute to an allele’s effect, and one may 
expect dominance deviation when variation acts in trans-. This is because effects due to a 
diffusible mediator are unlikely to be chromosome specific at the distant site. 
Approximately one-third of trait-associated SNPs examined in one study were identified as 
affecting distant DNA CpG methylation by Bonder et al. 15. Therefore, as I focussed on inter-
chromosomal genetic control of DNA CpG methylation, I fit a model explicitly including both 
additive and dominance genetic effects. 
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One method to assess trans- acting effects and their targets (e.g. transcription factor 
binding sites) is to use a molecular phenotype, such as DNA CpG methylation, that provides 
genome-wide coverage of targets. Unfortunately, previous studies attempting to analyse 
trans- acting genetic effects at scale and/or dominance effects have generally been 
underpowered. In the case of trans- acting control, power is reduced, in part, simply due to 
the greatly increased burden of multiple testing when including the remainder of the 
genome, rather than just the local region. In general terms, it is more difficult to identify 
dominance genetic effects compared to additive effects because of the construction of the 
model: additive effect estimates are based on the difference between the two 
homozygotes, i.e. 2 ’a’, whereas the dominance effect is the difference of the heterozygote 
from the midpoint of the two homozygotes, i.e. ‘d’ (Figure 4.1, Equation 4.1). In addition, if 
attempting the genome-wide coverage of both the genetic variants and the molecular 
phenotype, the number of tests increases in line with the product of independent variants 
and phenotypes. We present a well-powered, GWA study of DNA CpG methylation at 
573,027 CpG sites of 5,101 individuals from a single cohort measured using the Illumina EPIC 
array and assess additive and dominance genetic contributions simultaneously. Using these 
data, we analyse the molecular intermediates mediating the effect of inter-chromosomal 
SNPs and review enrichments at their targets. 
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Figure 4.1: Additive / Dominance genotypic values. 
Adapted from 146. The zero point on the line is the midpoint between the two homozygotes. 
Genotypic value is arbitrarily assigned as deviations from this value: the two homozygotes 
as ‘a’ and ‘-a’, and the heterozygote as ‘d’. Note that the sign of ‘a’ is dependent upon which 
allele (‘A’ or ‘B’) is coded as the effect allele in the regression, the sign of ‘d’ is not. In this 
case, if ‘BB’ represents the more methylated homozygote, the genotypic value of ‘AB’ is 
closer to that of ‘BB’ and is therefore more methylated than the midpoint of the two 






Generation Scotland: Scottish Family Health Study (GS) is a population- and family-based 
cohort from the Scottish population collected between 2006 and 2011 and has been 
described in detail elsewhere 114. 
 
All participants provided written informed consent and ethical approval was provided by 




Samples for DNA extraction (blood, or occasionally saliva) were obtained at the time of 
recruitment. Genotyping was carried out by the Genetics Core Laboratory at the Clinical 
Research Facility, University of Edinburgh, Scotland using the HumanOmniExpressExome-8 
v1.0 or v1.2 BeadChips with Infinium chemistry (Illumina). Genotypes were processed using 
the GenomeStudio Analysis software v2011.1 (Illumina) and called using BeadStudio-Gencall 
v3.0 (Illumina). The details of blood collection and DNA extraction are also provided 
elsewhere 115. 
 
Subsequent quality control removed individuals with <98% call rate, SNPs with <98% call 
rate, and SNPs with Hardy-Weinberg equilibrium p-value <1x10-6. After initial quality 
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control, 604,858 genotyped autosomal SNPs remained. The genotyped data were imputed 
utilising the Sanger Imputation Service to the HRC panel v1.1, as described previously by 
Nagy et al. 147. The data were pre-phased using SHAPEIT v2.r873 148 + duohmm12 103 and 
imputed with PBWT 149. 
 
Measurement of methylation 
Whole blood genomic DNA (500ng) was treated with sodium bisulfite using the EZ-96 DNA 
Methylation Kit (Zymo Research) and DNA methylation was assessed using Illumina Infinium 
MethylationEPIC BeadChip technology (Illumina), as per the manufacturer’s instructions. 
The arrays were scanned using an Illumina HiScan scanner (Illumina) and initial inspection of 
array quality was carried out using Illumina GenomeStudio Analysis software v2011.1 
(Illumina). 
 
Quality control of the DNA methylation data was carried out before normalisation. The R 
package shinyMethyl 150 was used for preliminary quality control. This quality control step 
removed 81 samples, based on the following criteria 1) overall array signal intensity and 
control probe performance outliers, 2) samples with a mismatch between recorded gender 
and predicted gender based on X and Y chromosome DNA methylation, and 3) genetic 
ethnic outliers for the cohort identified by principal component analysis 151. Further quality 
control was performed using the ‘pfilter’ function in the R package watermelon 152, samples 
were removed if ≥1% sites had a detection p-value of >0.05. This removed 18 further 
samples. Finally, this left 5,101 samples for further processing. Before normalization, 
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individual probe-sample pairs with a detection p-value of >0.05 were removed. 
Normalization was performed using function ‘preprocessNoob’ in the R package minfi 153. 
 
In order to remove potential technical confounders, linear mixed modelling was used to pre-
correct each probe. This model included the following fixed effects: top 50 principal 
components of control probe intensities (which explained 99% of variation in control probe 
intensities), appointment clinic centre, processing batch, year of the visit, and Sentrix 
position (position of the sample in Illumina slide); and the random effects: appointment 
date and Sentrix ID (Illumina slide). The model converged successfully for 712,595 sites, and 
the resultant residualised M-values were used as DNA methylation phenotypes in 
downstream analysis. For individual sites, outlier samples with residualised-M-values more 
than five interquartile ranges from the nearest quartile were removed. 
 
Finally, we fit biological covariates to create residuals for GWA. Cell-type proportions were 
estimated for granulocytes, monocytes, B-lymphocytes, natural killer cells, CD4+ T-
lymphocytes and CD8+ T- lymphocytes using the ‘estimateCellCounts’ function in R package 
minfi 153. The following mixed linear model was fit: Fixed effects) age, age2, gender, cell-type 
proportions for granulocytes, B-lymphocytes, natural killer cells, CD4+ T-lymphocytes and 
CD8+ T-lymphocytes, season of the visit, appointment time of the day, appointment day of 
the week; Random effects) genomic relationship matrices, G (genomic relationship matrix) 
and K (kinship relationship matrix), and three environmental relationship matrices, F 
(environmental matrix representing nuclear-family-member relationships), S (environmental 
matrix representing full-sibling relationships) and C (environmental matrix representing 
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couple relationships). The resulting residuals were inverse rank transformed prior to GWA 
analysis in a simple linear model. Data preparation and residualisation have been described 




A combined, additive and dominance, model was fit to the dataset (Equation 4.1; Figure 
4.1). Individuals were randomly split into a discovery set of 4,101 (set 1), and a replication 
set of 1,000 individuals (set 2). This model was fit to all CpG sites for which the 
residualisation had successfully completed (n = 573,027). 
 
Equation 4.1: 






<:;;3 + !;=><;=>3 + ?3 
 
- y is the residualised methylation values (above). 
- !@ABCDECFB  is the intercept term. 
- !*GG  and !G+"  are the additive and dominance effect-size estimates. 
- <*GGH is, for individual i, the sum of the minus probability of the genotypes AA plus 
the probability of the genotypes BB: -p(AA)+p(BB). 
- <IJKH is, for individual i, the probability of genotypes AB: p(AB). 
- ?@  is the error. 
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The model was fit to those SNPs that had total cumulative genotype count of >1 per 
genotype (N.B. subsequently filtered to ensure a total cumulative genotype count of >10 per 
genotype). Results for which the model p-value was <1x10-3 were retained. 
 
Post-GWA processing 
Maximal independent set 
The pairwise Pearson’s correlation coefficient of all CpG passing all quality control measures 
(n = 573,027) was calculated using the processed residualised phenotype data. A maximal 
independent set was calculated so that no pair of CpG in the resulting graph had a squared-
correlation coefficient >0.2. 512,601 CpG were present in the reduced set. 
 
LD clumping  
Genome-wide association results for CpG sites passing all quality control measures (n = 
573,027), for which a genomic location was reported in the Illumina EPIC array manifest (B3) 
(Illumina) present in the maximal independent set of CpGs are reported. Genetic variants 
were filtered to include only those with an imputation info score (SNPTEST v2) of >0.95. Per 
CpG, SNPs were clumped by linkage disequilibrium. That is, a lead variant (smallest p-value 
in the genome remaining un-clumped was selected) and variants on the same chromosome 
were clumped together if the squared Pearson’s correlation coefficient between the two 
was greater than 0.2. This process was repeated iteratively until all SNPs had been assigned 
to a clump. An unrelated set of European populations (CEU, FIN, GBR, IBS, and TSI) from the 
1,000 Genomes project 92,93 were used as the reference population for this procedure. 
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Finally clumps for which the lead variant had fewer than 10 of each genotype were 
removed. 
 
CpG and LD clumping (pre-regression analysis) 
Just as one can extend the concept of a 1D vector to a 2D matrix, the same is true for a 
standard Manhattan plot and the results presented here. That is, literally and figuratively, 
genome-wide methylation data adds an additional dimension to standard SNP data. If a 
standard Manhattan plot is a 1D vector of -log10(p-values), the stack of CpG Manhattan 
plots, one per CpG, can be thought of as a 2D matrix of -log10(p-values). Unfortunately, the 
SNPs are not independent of each other, and neither are the CpG. Genetic variants were 
filtered to exclude the required window: unconstrained analysis – SNP to CpG distance 
³50bp (in order to exclude technical variation); inter-chromosomal – SNP and CpG located 
on different chromosomes. SNPs with an imputation info score (SNPTEST v2) of £0.95, and 
those pairs for which the SNP was in LD (r2 >0.2) with any SNP within 10bp of the CpG site 
were also excluded. For each CpG site, the SNP with the largest F-statistic was then 
extracted. A process akin to LD clumping of SNPs was applied to the CpGs (Algorithm 1), and 
then standard LD clumping (Algorithm 1, but using SNPs and SNP correlations instead of 
CpGs and CpG correlations). 
 
These filtering steps result in a list of (quasi-) independent SNP:CpG pairs. An unrelated set 
of European populations (CEU, FIN, GBR, IBS, and TSI) from the 1,000 Genomes project 92,93 
was again used as the LD reference. Finally clumps for which the lead variant had fewer than 
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10 of each of each genotype were removed. Note that this is a very conservative analysis for 
the following reasons: 1) per CpG we take the maximum f-statistic for the model amongst all 
SNPs, therefore the number of SNPs included per CpG is limited to one, 2) the clumping of 
CpGs and SNPs were applied in series rather than together, and 3) minimum genotype count 
filtering was applied post-clumping. However, despite this, we still detect many significant 
SNP:CpG pairs. 
 
We performed the above separately for the discovery (set 1; n = 4,101) and replication (set 
2; n = 1,000) sets. 
 
Algorithm 1: 
1. List SNP:CpG pairs. 
2. Select the most significant (largest F-statistic) SNP:CpG pair yet to be 
clumped as the lead pair for a new clump and remove it from the list. 
3. Remove from the list, all SNP:CpG pairs for which the CpG is correlated 
(squared Pearson’s correlation coefficient) with the CpG of the lead pair 
with a value greater than 0.2. 
4. Repeat until the list is empty. 
 
Enrichment analysis using String 154 v11 
SNPs with a significant (Bonferroni correction: p-value <5x10-8/512,601) association (model) 
with any CpG (in the CpG and LD clumped results) were selected. This was performed for 
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both the unconstrained and inter-chromosomal sets. Significant locally- acting eQTL co-
localising with these SNPs were selected from the ‘whole blood’ results of GTEx (v6p) 13, the 
mapping window of which was limited to ±1Mb from the transcription start site. These 
Ensembl Gene IDs were converted to HGNC symbols using Ensembl Biomart (GRCh37) 155 
[accessed 25/06/2019] and input into String v11 154. ‘Gene type’ was extracted from, and 
defined by, Ensembl. 
 
I assessed: 1) the network of inter-chromosomal meQTLs (Bonferroni correction, 5x10-
8/512,601) under significant genetic control from the discovery set, 2) the network of inter-
chromosomal meQTLs (Bonferroni correction: p-value <5x10-8/512,601) under significant 
genetic control from the replication set, and 3) two randomly selected sets of 1,000 SNPs 
from GTEx (v6p) 13 and their associated eQTL. The randomly generated sets were used for 
comparison to ensure that the enrichment observed was not simply due to enrichment 
within GTEx itself, rather than that associated with the inter-chromosomal meQTLs. We 
considered enrichments in ‘Biological Process’ (GO) 156, ‘Molecular function’ (GO) 156, 
‘Cellular Component’ (GO) 156, ‘Reactome Pathways’ 157, ‘UniProt Keywords’ 158, ‘PFAM 
Protein Database’ 159, ‘INTERPRO Protein Domains and Features’ 160, and ‘SMART Protein 
Domains’ 161 as output by String.  
 
Mapping to all transcription factors 
SNPs with a significant (Bonferroni correction: p-value <5x10-8/512,601) association (model) 
with any CpG (inter-chromosomal; discovery set; CpG and LD clumped results) were 
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selected. Significant eQTL co-localising with these variants were selected from the ‘whole 
blood’ results of GTEx (v6p) 13, as above, and the Ensembl Gene IDs of those classified as 
‘protein coding’ in Ensembl (GRCh37), matched to all human transcription factors as 
identified by Lambert et al.30. Note that ENSG00000250312 (ZNF718) was misclassified in 
Ensembl GRCh37 155 [accessed 25/06/2019] as a lincRNA, this has subsequently been 
updated in Ensembl GRCh38 162 [accessed 24/10/2019]. ZNF718 has been included in the 
results as an addendum. 
 
Effect of increased trans- acting factor RNA on DNA CpG methylation at distant sites 
Taking the list of CpGs and LD clumped inter-chromosomal results, for each of the 
significant (Bonferroni correction, p-value <5x10-8/512,601) meQTL that co-localised with a 
locally- acting eQTL in whole blood from GTEx (v6p) 13, following effect allele harmonisation 
and removal of duplicate SNP and Ensembl gene IDs, linear regression analyses were 
performed as per Equation 4.2 and Equation 4.3. The construction of Equation 4.2 is to 
answer the question: is there an association between the allele that increases RNA 
abundance (locally- acting) and increases methylation on a different chromosome (inter-
chromosomal); and Equation 4.3 is such as to answer the question: is there an association 
between the dominance effect estimate on methylation of a different chromosome (inter-
chromosomal), orientated to the methylation status of the homozygote of the effect allele, 




Equation 4.2: meQTL additive beta estimate against eQTL beta effect estimate 
!"LMNN~	!#'* + intersect		
- !"LMNN  is the additive beta estimate from the meQTL study, as per Equation 4.1. 
- !#'*  is the eQTL beta effect estimate (estimated allelic effect) from GTEx (v6p) 13. 
 
Equation 4.3: meQTL dominance beta estimate against eQTL beta effect estimate 
!"LNWX ∗ Z3[4\!"LMNN]	~	!#'* + intersect		
- !"LNWX  is the dominance beta estimate from the meQTL study, as per Equation 4.1. 
- Z3[4\!"LMNN] is the sign of the additive beta estimate from the meQTL study, as per 
Equation 4.1, coded as -1 and 1, for negative and positive. 
- !#'*  is the eQTL beta effect estimate (estimated allelic effect) from GTEx (v6p) 13. 
- Note that the asterisk is a multiplication, not an implicit interaction set in the regression. 
 
Regression of additive and dominance effect estimates 
Taking the list of CpG and LD clumped results, significant (p-value < 1x10-13) inter-
chromosomal meQTLs, we fit !G+"  (dominance effect estimate) and |!*GG| (absolute 
magnitude of additive effect estimate) against a base-model (Equation 4.4 and Equation 4.5) 
including: the other of !G+"  and |!*GG| plus the frequencies of the heterozygote and minor 
homozygote, the SNP and CpG chromosomes (as a categorical variable), the minor allele 
type (as a categorical variable), and whether the CpG is located within a CpG island (based 
on the UCSC 163,164 [accessed 23/06/2019] track ‘cpgIslandExt’), and the SNP or CpG 
annotation in question based on its genomic position (Equation 4.4 and Equation 4.5). 
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Annotations, as provided as part of the LOLA 165 package, were used from Cistrome 166 – 
epigenome (histone marks), Codex 167 (transcription factors), and Encode segmentation 
(‘wgEncodeAwgSegmentation’) 163,164,168. Annotations were fit one at a time, to both SNP 
and CpG location, and considered to be significantly associated if they passed a, within 
collection, Bonferroni correction. We fit the model within the discovery set and attempted 
to replicate those that reached Bonferroni significance in the discovery set. 
 
Equation 4.4: Magnitude of dominance effect regression 
!G+"	~	|!*GG| + Chr&'( +	ChraFb + Allele"@AeD + Freqh@AeD	iehejkleBC + FreqiCBCDejkleBC + CpGisland +
	annotation + intersect  
 
Equation 4.5: Absolute magnitude of additive effect regression 
|!*GG|	~	!G+" + Chr&'( +	ChraFb + Allele"@AeD + Freqh@AeD	iehejkleBC + FreqiCBCDejkleBC + CpGisland +
	annotation	 + 	intersect 
 
- !G+"  is the effect-size estimate for dominance, as defined in Equation 4.1. 
- |!*GG| is the absolute magnitude of the effect-size estimate for additivity, as defined 
in Equation 4.1. 
- Chr is chromosome, the subscript defines which location it refers to, SNP or CpG, 
dummy coded. 
- AlleleMinor is the minor allele type, dummy coded. 
- Freq is the genotype frequency of the minor homozygote and heterozygote, as 
referred to in the subscript. 
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- CpGisland is the CpG within a CpG island as defined in UCSC 163,164 [accessed 
23/06/2019] track ‘cpgIslandExt’), binary variable. 
 
Results 
Methylation quantitative trait loci are abundant throughout the genome 
We demonstrate widespread genetic control of CpG methylation (Figure 4.2), including both 
additive, and dominance genetic control of CpG methylation (Table 4.1). In a maximal 
independent set of CpGs (squared-correlation <0.2 between any pair of CpG sites), following 
LD clumping (Methods) we identify 683,842 significant (Bonferroni correction for multiple 
testing) SNP:CpG pairs: representing significant genetic control of 177,032 CpGs (34.5%; n = 
512,601), and 442,218 SNPs in the discovery set (n = 4,101). Of these, 262,816, 110,527, and 
204,141, respectively, replicate (n = 1,000; Table 4.1). 
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Table 4.1: The number of SNP:CpG pairs in each meQTL set. 
Bonferroni correction for multiple testing used throughout, see main text for full 
description. When listed as discovery / replication, the SNP:CpG pairs that were found to be 
significant in the discovery set were looked up in the replication set, and the significance 
threshold determined by the number of significant results in the discovery set. However, 
when listed as ‘set 1’ and ‘set 2’, the two sets were assessed independently, with Bonferroni 




(discovery / set 1) 
Size 
(replication / set 2) 
LD clumped, minimum independent CpG set, model significant 
(discovery / replication) 
683,842 262,816 
LD clumped, minimum independent CpG set, model significant 
(discovery / replication), additive control (set 1 / set 2) 
555,928 190,005 
LD clumped, minimum independent CpG set, model significant 
(discovery / replication), dominance control (set 1 / set 2) 
11,143 3,137 
LD and CpG clumped, locally- acting genetic control 
(set 1 / set 2) 
43,143 26,001 
LD and CpG clumped, locally- acting additive genetic control 
(set 1 / set 2) 
40,421 25,117 
LD and CpG clumped, locally- acting dominance genetic control 
(set 1 / set 2) 
5,562 1,990 
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LD and CpG clumped, inter-chromosomal genetic control 
(set 1 / set 2) 
3,364 1,333 
LD and CpG clumped, inter-chromosomal additive control 
(set 1 / set 2) 
3,161 1,294 
LD and CpG clumped, inter-chromosomal dominance control 





Of the 683,842 (discovery), and 262,816 (replication) SNP:CpG pairs under significant 
(Bonferroni correction: p-value <5x10-8/512,601, and <0.05/683,842, respectively) genetic 
control, 555,928, and 190,005 demonstrate significant additive control (Bonferroni 
correction: p-value <0.05/683,842, and <0.05/262,816), and 11,143 and 3,137 demonstrate 
significant dominance control (Bonferroni correction, <0.05/683,842, and <0.05/262,816), 
respectively. Note that the replication set is approximately 4-times smaller than the 
discovery set. 
 
Locally- acting genetic control of DNA CpG methylation is very common 
Locally- acting genetic control of CpG methylation is very common, as can be seen from 
Figure 4.2. The diagonal line on this figure represents independent (LD clumped; Methods) 
meQTLs for which the genomic location (chromosome, position) of the SNP is close to the 
CpG location. Following CpG and LD clumping, we identified 43,143 significant locally-acting 
(SNP to CpG distance between 50bp and 1Mb) meQTLs in set 1, and 26,001 in the set 2 
(Bonferroni correction: p-value <5x10-8/512,601). Of these, 93.7% and 96.6% exert 
significant (40,421 and 25,117; Bonferroni correction: p-value <0.05/43,143 set 1, and 
<0.05/26,001 set 2) additive genetic control, respectively; and 12.9% and 7.7% exert 
significant (5,562 and 1,990; Bonferroni correction: p-value <0.05/43,143 set 1, and 
<0.05/26,001 set 2) dominance control (Table 4.1). 
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Figure 4.2: Aerial view of Manhattan (plot) 
Plot of SNP genomic location to CpG genomic location for all significant, replicated 




Inter-chromosomal genetic control of DNA CpG methylation is also widespread 
Inter-chromosomal genetic control, by definition, involves at least two distinct loci. 
Following CpG and LD clumping, I identify, 3,364 significant (0.7%; Bonferroni correction: p-
value <5x10-8/512,601) inter-chromosomal SNP:CpG pairs (set 1) and 1,333 significant 
(0.3%; Bonferroni correction: p-value <5x10-8/512,601) pairs (set 2). I investigate the 
potential molecular intermediates below. 
 
Molecular intermediates of inter-chromosomal meQTLs 
C2H2 zinc-finger proteins (± KRAB domain) 
We delineate the molecular intermediates of inter-chromosomal genetic control of DNA 
CpG methylation by mapping the meQTLs under significant (Bonferroni correction, p-value 
<5x10-8/512,601) inter-chromosomal genetic control (separately for both set 1 and set 2) to 
significant locally- acting eQTL in whole blood using GTEx (v6p) 13 and performing gene-set 
enrichment analyses using String v11 154 (Methods). In general terms, we find strong 
enrichments for C2H2-ZF proteins, especially those containing a KRAB domain, as well as 
enrichments for transcriptional processes (Table 4.2). Of those significant in the discovery 
set, all successfully replicate (Bonferroni correction, p-value <0.05/17), and the odds ratios 
in the discovery set range from 2.15 to 3.76. As the replication set was analysed in parallel 
to the discovery set from the point of residualisation onwards, including the application of 
multiple-testing corrections, it is interesting to note that the odds ratios are uniformly 
larger, and the p-values smaller, in the replication set. This implies that the locally- acting 
eQTL of the proteins in these sets, are those associated with the most significant inter-
	 101	
chromosomal meQTL (i.e. those that remain discoverable in the smaller replication set). 
Clearly, there is correlation amongst the annotations in Table 4.3, however, these broadly 
encompass the nested sets of KRAB domain containing transcription factors, C2H2 
transcription factors, and transcription itself. 
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Table 4.2: Enrichments amongst the genes of the locally- acting eQTL co-localising with inter-chromosomal meQTL. 
Significant enrichments amongst whole blood locally- acting eQTL from GTEx (v6p) 13 that 
co-localise with an inter-chromosomal meQTL, when compared to a randomly chosen set of 
whole blood locally- acting eQTL. Bonferroni correction in discovery based on 9,099 tested 
annotations. Odds ratios are: odds in eQTL set co-localising with an inter-chromosomal 
meQTL over the odds in random eQTL set. p-values are Fisher’s Exact test p-values. 
Enrichment information from String v11 154. All enrichments from the discovery set replicate 
successfully. Number of proteins in sets: discovery 590, random background one 798; 
replication 278, random background two 791. 
 
 








Pfam PF00096 Zinc finger, C2H2 type 3.43 4.73x10-9 5.61 5.02x10-12 
InterPro IPR036236 Zinc finger C2H2 superfamily 3.13 3.00x10-8 5.76 1.83x10-12 
InterPro IPR013087 Zinc finger C2H2-type 3.04 5.99x10-8 5.76 1.83x10-12 
SMART SM00355 zinc finger 2.96 9.48x10-8 5.35 7.70x10-12 
InterPro IPR036051 KRAB domain superfamily 3.76 2.43x10-7 6.04 2.95x10-10 
Pfam PF13912 C2H2-type zinc finger 3.37 2.63x10-7 5.53 3.82x10-10 
InterPro IPR001909 Krueppel-associated box 3.65 3.54x10-7 5.92 2.33x10-10 
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Keyword KW-0804 Transcription 2.20 4.58x10-7 3.11 2.85x10-9 
Process GO:0006351 transcription, DNA-templated 2.15 5.25x10-7 3.11 9.05x10-10 
Process GO:0097659 nucleic acid-templated transcription 2.15 5.25x10-7 3.11 9.05x10-10 
Process GO:0032774 RNA biosynthetic process 2.15 5.25x10-7 3.11 9.05x10-10 
Function GO:0003700 DNA-binding transcription factor activity 2.38 5.45x10-7 3.91 9.09x10-11 
Function GO:0000981 
DNA-binding transcription factor activity, 
RNA polymerase II-specific 
2.37 6.42x10-7 3.99 1.56x10-10 
SMART SM00349 krueppel associated box 3.24 7.32x10-7 5.45 2.93x10-10 
Function GO:0140110 transcription regulator activity 2.25 7.59x10-7 3.25 3.39x10-9 
Pfam PF01352 KRAB box 3.25 1.42x10-6 5.53 3.82x10-10 
Keyword KW-0805 Transcription regulation 2.16 1.84x10-6 3.22 3.05x10-9 
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All known transcription factors 
The 3,364 significant (discovery set; Bonferroni correction: 5x10-8/512,601) inter-
chromosomal meQTLs we identify were also locally- acting eQTL for 835 unique Ensembl 
gene IDs in whole blood in GTEx (v6p) 13. Of these, 599 are reported to be protein coding by 
Ensembl (GRCh37). 15.7% (94/599) of the protein coding genes are recognised transcription 
factors 30, and, of these, 77.7% (73/94) are C2H2-ZF proteins (Table 4.3). Of those identified 
as transcription factors, we find a non-replicated association between the additive meQTL 
effect estimate and the allelic effect eQTL effect estimate (Equation 4.2; p-value 9.97x10-4 
and 0.22, set 1 and set 2, respectively) and no significant relationship with respect to 
dominance (Equation 4.3; p-value 0.66 and 0.93, set 1 and set 2, respectively). It is however 
worth noting that we are not surveying the full distribution of meQTL, or eQTL model p-
values in this analysis and so these results should be interpreted with caution (Figure 4.3). 
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Figure 4.3: eQTL allelic effect estimates to meQTL effect estimate plots 
All significant (discovery set; Bonferroni correction; <5x10-8/512,601) inter-chromosomal 
meQTL that co-localised with a locally- acting eQTL in whole blood from GTEx (v6p) 13. 







Table 4.3: Binding domains of the known transcription factors identified from significant inter-chromosomal meQTLs as 
significant locally- acting eQTL, protein-coding only 
‘Frequency: meQTL’: the frequency of the DNA binding domain amongst those transcription 
factors identified for which the inter-chromosomal meQTL (discovery set) is a locally- acting 
eQTL in whole blood.  
‘Frequency: all known’: the frequency of the DNA binding domain amongst all transcription 
factors identified by Lambert et al. 30. 
 
 
DNA binding domain 
Frequency 
meQTL (all known) 
DNA binding domain 
Frequency 
meQTL (all known) 
C2H2 73 (759) Forkhead 1 (49) 
bHLH 4 (108) GATA 1 (10) 
Homeodomain 3 (228) HSF 1 (8) 
bZip 2 (54) mTERF 1 (4) 
IRF 2 (9) Paired box 1 (9) 
CG-1 1 (2) T-box 1 (17) 
DM 1 (7) Unknown 1 (69) 




In addition, of those proteins not identified as transcription factors, 18.9% (7/37) are 
identified as low specificity DNA binding proteins, and 16.2% (6/37) are identified as 
ssDNA/RNA binding. 
 
It is noteworthy that, of the 599 protein coding genes that we identified as linked to inter-
chromosomal meQTLs, 107 (17.9%) are confirmed as DNA or RNA binding by orthogonal 
methods, and 94 (15.7%) are recognised as bona fide transcription factors in the most 
comprehensive catalogue available to-date 30. 
 
Interestingly, ZNF718 (ENSG00000250312) was not included in these results as it was 
incorrectly identified as a lincRNA in Ensembl GRCh37 155 [accessed 25/06/2019], since 
updated in Ensembl GRCh38 162 [accessed 24/10/2019] to protein coding. It is however, a 
C2H2-ZF protein and was classified as a transcription factor in the results of Lambert et al. 
30. 
 
Strikingly, these results represents 5.8% of all known or likely human transcription factors 
(95/1639), 9.7% (74/759) of all known human C2H2-ZF transcription factors, and 14.8% 
(53/357) of all known human Krüppel associated-box (KRAB) containing transcription factors  
30. C2H2 DNA binding domains are strongly over-represented, comprising 77.9% (74/95) of 
those transcription factors identified as associated with a locally- acting eQTL that co-
localises with an inter-chromosomal meQTL (in the LD and CpG correlation filtered discovery 
set), as compared to 45.0% (759/1,686) of all known human transcription factors 30 (odds 
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ratio 4.30, Fisher’s exact p-value 2.62x10-10). As are KRAB containing transcription factors, 
comprising 55.8% (53/95), and 21.8% (357/1,639), respectively (odds ratio 4.53, Fisher’s 
exact test p-value 3.59x10-12). 
 
Trans- acting hubs 
As can be seen from Figure 4.2, there are clear trans- acting ‘hubs’ or ‘hotspots’ (vertical 
lines on the plot), where a single SNP (or group of closely located SNPs) influences the 
methylation level at multiple CpG sites. This recapitulates, albeit at greater resolution, a 
known meQTL result 12, and one that parallels expression data 169. Taken as representative 
of C2H2-ZF containing proteins, the 74 proteins present in our network that were in the 
PFAM ‘Zinc finger, C2H2 type’ (PF00096) class (Table 4.3) were tagged by 76 independent 
(LD r2 <0.2) SNPs. Of these 76 SNPs, 46% (35/76) were present on chromosome 19. This may 
contribute to the enrichment of trans- acting meQTLs found on chromosome 19, seen here 
(Figure 4.2) and previously 12. 
 
Factor binding site CpG methylation under inter-chromosomal dominance genetic control 
There are a number of theories that have been proposed to explain the molecular basis of 
dominance 170: 1) dominant-negative mutations, 2) haploinsufficiency, and 3) gain-of-
function mutations. Whilst it is sufficient for these mechanisms to be intra-locus to generate 
dominance effects, it is not necessary, and there is emerging interest in the genesis of 
dominance effects by regulatory networks and inter-locus interactions 170,171. Classically, 
given a shared nuclear environment, trans- genetic effects are felt to imply a diffusible 
	 109	
mediator rather than direct genomic interaction, further supporting the hypothesis of inter-
locus interaction. Transcription factors are the canonical trans- acting molecules and can 
affect multiple sites within the genome in both a sequence and methylation specific manner 
140,141 and are of clear importance in cellular regulatory mechanisms. 
 
Of the 3,364 significant (Bonferroni correction: p-value <5x10-8/512,601; Table 4.1) inter-
chromosomal SNP:CpG pairs (set 1) and 1,333 significant (Bonferroni correction: p-value 
<5x10-8/512,601) pairs (set 2), 302 and 122 pairs, respectively, show a significant 
(Bonferroni correction: p-value <0.05/3,364, and <0.05/1,333 respectively) dominance 
component and 3,161, and 1,294 a significant (Bonferroni correction: p-value <0.05/3,364 
and <0.05/1,333) additive component. 
 
As I have demonstrated, C2H2-ZF transcription factors , especially KRAB domain containing 
transcription factors , as well as other transcription factors are implicated in the inter-
chromosomal genetic control of DNA CpG methylation. Given this, I hypothesised that inter-
chromosomal genetic control of DNA CpG methylation, especially dominance control, of 
CpG methylation at the Chip-Seq peaks of a given protein may implicate the protein itself, or 
its binding partners, as the cause of the variation in methylation. 
 
With respect to Chip-Seq results (Codex 167) and histone marks (Cistrome 166 Epigenome), 
replicated associations are uniformly associated with increasing dominance effects on CpGs 
within Chip-Seq peaks (Supplementary Table 11). This implies that, for CpG within the Chip-
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Seq peak, the methylation status of the heterozygote is more similar to the more 
methylated homozygote (Figure 4.1). Replicated histone marks associated with increased 
dominance genetic control of CpGs within the locus (Bonferroni correction: discovery p-
value <0.05/21; replication p-value <0.05/9) included: Acetylated H3, H3K4me2, H3K4me3, 
H3K9ac, H3K9me3, H3K9K14ac, and H3K14ac. Replicated Chip-Seq peaks associated with 
increased dominance genetic control of CpGs within the locus are in Table 4.4. Interestingly, 
when absolute magnitude of additive effect was analysed as the dependent variable (rather 
than magnitude of dominance effect; i.e. Equation 4.5 rather than Equation 4.4), there was 
only one replicated result: an association between H3K9K14ac and absolute additive effect. 
 
Finally, we used data from ENCODE to assess the seven genomic-segmentation states of the 
combined ChromHMM and Segway segmentation  163,164,168 and found strong replicated 
(Bonferroni correction: discovery p-value <0.05/14; replication p-value <0.05/4) evidence 
for an association of CpG location within predicted transcription start-sites and increased 
dominance control (discovery p-value <2x10-16; replication p-value <2x10-16), transcribed 
regions and reduced dominance control (discovery p-value 6.35x10-15; replication p-value 
6.20x10-8), and weaker, but still clearly replicated evidence, for predicted repressed or low 
activity regions (discovery p-value 3.01x10-9; replication p-value 3.74x10-3) indicating a 
complex relationship between the inter-chromosomal meQTLs, their target sites, and 
predicted transcription profiles. The Chip-Seq peaks that we identify (Table 4.4), and the 
transcription factors we identify as acting between chromosomes do not overlap (match 
based on HGNC symbol). This implies either that there is modulation of the DNA CpG 
methylation within the region, for example through spreading of DNA CpG methylation from 
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the binding sites of the KRAB factors to encompass the binding sites of these transcription 
factors, or limitations due to lack of statistical power. Note that this result does not impact 
those Chip-Seq analyses the target of which is not a transcription factor. 
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Table 4.4: Replicated Chip-Seq peaks associated with increased dominance genetic control of CpGs within the locus. 
Replicated Chip-Seq peaks associated with increased dominance genetic control of CpGs 
within the locus. Discovery p-value threshold: <5.21x10-4 (0.05/96); Replication p-value 











core-binding factor subunit 
beta 
 
CBFB is a co-factor: augments 
the binding of RUNX to DNA 172. 
CDK7 cyclin dependent kinase 7  
Serine/threonine kinase involved 
in cell cycle control and in RNA 
polymerase II-mediated RNA 
transcription. Phosphorylates, 
amongst other things, POLR2A 
158 [accessed 24/10/2019]. 
EP300 E1A binding protein p300  
EP300 is a co-factor.  It has many 
motifs, presumably because 
many transcription factors 
recruit it. 
ERG ETS transcription factor ERG Yes  
ETS1 
ETS proto-oncogene 1, 
transcription factor 
Yes  
HDAC1 histone deacetylase  HDAC1 is likely to be a co-factor. 
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MED21 mediator complex subunit 21  
MED21 does not contact DNA in 
the structure of the yeast 





MYH11 myosin heavy chain 11  
Assayed in leukaemia cell lines 
harbouring inv(16) translocation 
(CBFB-MYH11). Therefore, it can 
be thought of as also targeting 
CBFB. 
NOTCH1 notch receptor 1  
A transmembrane protein that 
inhibits MEF2C activation 173. 
NOTCH1 does not bind DNA in 
the structure PDB:4J2X, nor is it 
required for DNA binding by 
RBPJ. 
PHF8 PHD finger protein 8  
Histone lysine demethylase, with 
selectivity for mono- and di-
methyl states 158 [accessed 
24/10/2019]. 
 POLR2A RNA polymerase II subunit A   
RUNX1 








TCF3 transcription factor 3 Yes  




I identify many CpGs in Chip-Seq peaks that appear to be under inter-chromosomal 
dominance genetic control (Supplementary Table 11). In addition, I identify, using only 
meQTL and eQTL data, 5.8% of all known human transcription factors, 9.7% of all known 
human C2H2-ZF transcription factors, and 14.8% of all known human Krüppel associated-
box (KRAB) containing transcription factors as having an eQTL that controls their abundance 
that also co-localises with an inter-chromosomal meQTL. 
 
I demonstrate significant enrichment for C2H2-ZF and KRAB containing proteins in the set of 
inter-chromosomal meQTL associated locally- acting eQTL, when compared to a background 
of proteins associated with significant eQTL of whole blood (Table 4.2), as well as a 
significant enrichment of C2H2-ZF DNA binding domain and KRAB containing transcription 
factors amongst all known human transcription factors (odds ratio 4.30, Fisher’s exact p-
value 2.62x10-10, and odds ratio 4.53, Fisher’s exact p-value 3.59x10-12, respectively). 
 
KRAB zinc-finger proteins are encoded by an ancient group of genes, first emerging about 
400 million years ago in a common ancestor of coelacanths, lungfish and tetrapods 174,175. 
KRAB zinc-finger proteins are the largest family of transcriptional regulators in higher 
vertebrates 175, and humans encode 357 30. The proposed molecular functions of KRAB zinc-
finger proteins include transcriptional repression of the promoters of RNA polymerases I, II, 
and III 176, RNA binding and splicing 176, and a complex ‘domestication’ of transposable 
elements 175. Many, although not all 175, KRAB zinc-finger proteins interact with KAP1 to 
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form a repression complex containing the histone methyltransferase SETDB1 177  the 
nucleosome remodelling and deacetylation (NuRD) complex 178, heterochromatin protein 1 
(HP1) 179–182, and DNA methyltransferases 31. Quenneville et al. 31 have previously 
demonstrated that, in embryonic stem cells, KAP1 mediates DNA CpG methylation, and that 
this methylation spreads over short distances (3 to 5kb; or further in other studies 32) so as 
to involve nearby CpG islands. In addition, in a murine conditional gene regulation system, 
KRAB-mediated repression was seen to result in promoter DNA methylation and irreversible 
gene silencing when allowed to occur in early mouse embryogenesis 183. However, the same 
phenomenon was not observed in differentiated cells, suggesting a temporal context to the 
repression. That is, in differentiated cells, the KRAB/KAP1-induced heterochromatin 
formation did not lead to corresponding DNA CpG methylation changes. Our results 
represent a potential extension of this framework to haematopoietic stem cells and their 
progeny. Indeed, the role of KRAB zinc-finger proteins in mitophagy during erythrogenesis 
has recently been established 184. On top of this temporal context, previous work has 
demonstrated that repression by KRAB factors also demonstrates specificity with respect to  
genomic context 185. The results presented here demonstrate one possible solution to the 
problem of identifying the native genomic targets, and hence contexts, of endogenous KRAB 
domain containing transcription factors. 
 
All the transcription factors identified as co-localising with an inter-chromosomal meQTLs 
here, are thought to bind as a monomer or homomultimers to DNA 30. However, the binding 
motif is unknown in 27.4% (26/95) 30. The results presented here clearly provide a potential 
method for identifying the CpG targets of these factors. A recent work identifying the 
	 117	
impact of DNA CpG methylation on binding specificities of human transcription factors 
examined whether the motifs they identified when DNA CpG methylation was considered 
was similar or dissimilar to that identified by previous studies. 28.5% of the motifs identified 
that were different from that identified in preceding studies were C2H2-ZF proteins, 
compared to only 8.5% of those that were similar 141. The cause of this discrepancy was 
commonly because the transcription factors binding specificity had not previously been 
determined, or whose preference for methylated cytosine had not previously been 
appreciated 141. Of the 759 known C2H2-ZF transcription factors 30, about 100 were analysed 
by Yin et al. 141, and of these approximately one third were shown to preferentially bind 
some methylated sequences over the corresponding unmethylated sequence. However, 
with respect to binding affinity, a methylated cytosine may be more similar to a thiamine 
than to an unmethylated cytosine in its binding motif 186, and so this situation is more 
complex than simply comparing methylated to unmethylated, but otherwise identical, 
sequences.  
 
A limitation of this study is that we were unable to distinguish between different types of 
cytosine methylation, e.g. 5-methyl-cytosine, 5-hydroxy-methyl-cytosine, 5-formyl-cytosine, 
and 5-carboxy-cytosine, the differences in which may impact transcription factor binding 
and regulatory feature response 187. Therefore, meQTL that are specific to a particular 
methylation subtype may be missed. In addition, as with any study, we are faced with the 
impossibility of excluding all confounders, e.g. residual cell-type composition bias. However, 
only 12% of KRAB-containing C2H2-ZFs are thought to be tissue specific 30. This, together 
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with the abundant nature of the meQTLs identified, make this explanation of the results 
unlikely. 
 
C2H2-ZF proteins contribute the greatest amount of motif diversity to the pool of motifs 
recognised by human transcription factors 30. It has previously been shown that KRAB zinc-
finger protein binding correlates with H3K9me3 at their target loci 31,174. We demonstrate 
that, as with all other replicated Chip-Seq peaks (Supplementary Table 11), H3K9me3 was 
associated with increased dominance genetic control of DNA CpG methylation. 
 
It is estimated that approximately 93% of common disease-associated genetic variation is 
non-coding 11 and it has been shown that disease-associated genetic variation can have 
distantly- acting (>5Mb SNP to CpG distance, or located on different chromosomes) effects 
on DNA CpG methylation 15. Indeed, it was found that approximately one third of trait-
associated variants affected methylation at distant sites 15. Amongst the inter-chromosomal 
meQTLs identified in our study, we have shown strong enrichment for C2H2-ZF proteins, 
especially those containing KRAB domains. Given the genome-wide coverage of both the 
SNP and CpG sites in this study, it enables the possibility of using the results as a dictionary 
to look up both the likely local and distant effects of genetic variation found to be disease 
associated. That is, one could take the SNPs identified as disease associated from a GWA 
study and attempt to identify which other genomic locations are affected by their variation 
by mapping the location of the CpGs affected by their variation, in an analysis similar to that 




I have identified 5.8% of all known human transcription factors – including 9.7% of all known 
human C2H2-ZF protein transcription factors, and 14.8% of all known human Krüppel 
associated-box (KRAB) containing transcription factors – as affected by a locally- acting eQTL 
that is also an inter-chromosomal meQTL. I also highlight the abundance of non-additive 
genetic effects driving variation of DNA CpG methylation at distant CpGs. I review the 
enrichment of these loci for the binding of many protein complexes and find this to be 
common. 
 
Based on genomic location, it has previously been proposed that distantly- acting meQTL co-
localise with genomic regions containing zinc-finger containing transcription factors 21. I 
extend this result and find strong enrichment for variation in the expression of C2H2-ZF 
proteins (using locally- acting eQTL data), especially those containing a Krüppel associated 
box (KRAB) domain. In addition, I go on to highlight numerous protein complex binding sites 
within which DNA CpG methylation is enriched for inter-chromosomal dominance genetic 
control. 
 
In this chapter I have illuminated a small part of the complex regulatory landscape of the 
cell. This work has important implications for the unpicking and interpretation of non-coding 
GWA variants in both health and disease. As much of GWA disease associated variation is in 
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non-coding regions, understanding the regulatory networks of the cell is of critical 
importance in the post-GWA study era. 
 





Summary of main findings 
This thesis includes three studies of intermediate traits, and examines their utility in 
illuminating the pathways between genetic variation and phenotype. I undertook the 
assessment of both plasma and cellular protein abundance, as well as DNA CpG 
methylation. 
 
In Chapter 2, I conducted the genome-wide association of 249 proteins, as measured in 
plasma, using an antibody-based assay in two European populations. I used the results of 
this to perform proteome-by-phenome MR and demonstrated 509 putative causal links 
between various proteins and outcome diseases and traits, including such links to 
cardiovascular disease and schizophrenia. 
 
In Chapter 3, I demonstrated the feasibility of examining the cellular proteome of peripheral 
blood mononuclear cells and presented an exploratory analysis of the results of the first 251 
samples. I compared these results with those found for RNA expression in whole blood from 
the GTEx (v6p) project 13. This chapter represents the deepest assessment of the proteome 
of human peripheral blood mononuclear cells at a population-scale to date. We find 
evidence for a causal contribution of both members (PADI2 and PADI4) of the ‘histone H3-
R26 citrullination’ pathway (GO:0036413) in rheumatoid arthritis, as well as demonstrate a 
putative method for assessing pleiotropic effects of any given SNP using meQTL data. 
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In Chapter 4, I unpacked the molecular mechanisms underlying inter-chromosomal meQTL 
by combining the results generated here with those of the GTEx (v6p) project 13. I identified 
95 locally- acting eQTL for transcription factors that are also inter-chromosomal meQTL. 
Among these I demonstrated a significant enrichment for C2H2-ZF and Krüppel associated-
box (KRAB) containing transcription factors. In addition, I demonstrated an enrichment for 
C2H2-ZF and KRAB containing transcription factors amongst eQTL that co-localise with an 
inter-chromosomal meQTL amongst all significant whole blood locally- acting eQTL in GTEx 
(v6p) 13. This suggests that C2H2-ZF and KRAB containing transcription factors may be the 
molecular intermediates mediating the effects of inter-chromosomal meQTL. In addition, I 
find that CpG affected by an inter-chromosomal meQTL may be found in those parts of the 
DNA that interact with many different protein complexes, suggesting that trans- acting 
effects on methylation may be widespread and not just limited to the direct effects of 
transcription factors, but of their binding partners, and the entire regulatory network. 
 
Limitations 
An easy dichotomy to draw is between theoretical and practical limitations encountered. 
Theoretical 
First and foremost, there is the issue of statistical power, in particular with respect to the 
two proteomics studies presented here. However, sample size in all cases was governed by 
external constraints. An obvious solution to this is meta-analysis and my consortia 
contributions are mentioned in the preface to this thesis. Thankfully, given the initial 
promising results of the peripheral blood mononuclear cell proteomics project, when 
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complete the sample size for this study will be approximately 3.4 times larger than that 
discussed here. Compounding issues of statistical power, in the context of multiple 
correlated outcomes a Bonferroni correction is likely to be extremely cautious and will 
clearly have downstream consequences for those SNPs selected for follow-up. In order to 
address this, at various points throughout this thesis, a more permissive FDR threshold has 
been used. 
 
Throughout this thesis, the 1,000 Genomes 92,93 dataset was used as an LD reference. Due to 
the reduced number of SNPs present in this data when compared to the HRC 104 imputed 
data used for genome-wide association, there will have been a consequent loss of 
resolution when picking lead-SNPs for downstream analyses. 
 
Fundamental to the legitimacy of the results of MR are the following assumptions: 1) that 
the SNP is associated with the exposure of interest, 2) that the SNP is independent of any 
confounders, and 3) that the SNP does not influence the outcome of interest, except via the 
exposure variable 26. It is also assumed that the relationship between the exposure and 
outcome is linear 26. Assumption 3 could be stated another way, that is, that the genetic 
variant does not exhibit horizontal pleiotropy. Assumptions 2 and 3 are clearly untestable 
given the impossibility of measuring all possible confounders and pathways between 
instrumental variable and outcome. However, a priori knowledge of the biology of the 
system can be leveraged to, in part, address concerns about their validity. In addition, as 
alluded to in Chapter 3, by increasing the depth to which the proteome is assessed, it is 
possible to enact a more thorough assessment of the pleiotropic effects of any given SNP by 
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virtue of measuring more of the potential intermediate variables between SNP and outcome 
trait. For example, in this context, these intermediate traits could be all the proteins 
encoded within 1Mb of the SNP. 
 
In addition, while a significant MR result implies that the exposure affects the outcome, it 
does not provide specific information as to when the protein exerted its effect, nor the 
relevant tissue within which this modulation occurred. Both of these influence the 
practicality of using a particular protein as a therapeutic target. 
 
Finally, at various points in this thesis an appeal to a priori biological knowledge has been 
used to make inference regarding direction of causation. That is, that the proximity of a 
genetic variant altering the abundance of an RNA or a protein to the gene encoding that 
RNA / protein implies a direct causal link between the variant and RNA / protein abundance. 
However, this is not absolute, and reverse causation (e.g. SNP -> disease outcome -> protein 
abundance) cannot be excluded. Methods of causal discovery (that is to attempt to 
ascertain the underlying causal graph from the data) do exist in the context of Mendelian 
Randomisation, for example bidirectional (reciprocal) MR 188, and MR Steiger 189, and may 
be useful in future work. 
 
Practical 
Given the number of the entities measured by ‘-omic’ technologies the computational 
challenges in their analysis are substantial. This poses problems both in the processing of 
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these data and the subsequent storage of the results. For example, despite compression of 
the output data, and restriction of the number of significant digits stored, we were only able 
to store SNP:CpG results with a model p-value of <1x10-3 for the meQTL analyses. In filtering 
the results for storage in this manner, it does unfortunately limit the use of these data in 
analyses that require full summary statistics. However, given some assumptions about the 
distribution of these data, it may be possible to impute the missing results in the 1x10-3 to 1 
range. 
 
As discussed in Chapter 4, the binding specificities of antibody-based assays (such as the 
Olink assay used in Chapter 2) are not perfect and are vulnerable to any variation that 
causes a conformational change in the protein that affects the epitope of the antibody. An 
analogous issue exists with the mass-spectrometry results in that non-synonymous changes 
to the protein will potentially change its mass, elution profile, and digestion fragments. 
However, for directly measured – or well imputed – non-synonymous variants in the mass-
spectrometry data-set, this is a surmountable problem. In an individual harbouring a non-
synonymous variant, the mutant protein is likely to have been directly measured and 
recorded in the raw mass-spectrometry data. It is theoretically possible to include all non-
canonical protein sequences in the peptide / protein search of the output data. However, 
the computational and multiple testing burdens of such and analysis should not be 
underestimated. Finally, unknown proteins cannot be quantified using the current method 
of searching that matches measured spectra to those predicted by an in-silico digest of all 
known proteins. This reinforces the necessity to analyse features directly. 
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Potential Future Directions 
Proteomics 
As the peripheral blood mononuclear cell work is an exploratory analysis and only 
approximately 30% of the predicted final sample size, the entire chapter is forward-looking. 
There are many exciting future possibilities with this data set, as summarised in Chapter 4 
and briefly recapitulated here: analysis of the correlation structure of the proteins and 
outlier removal, the investigation of alternative imputation strategies, and the inclusion of 
further cell-type specific markers in the regression model (for example CD3, CD19, and CD14 
to tag T-lymphocytes, B-lymphocytes, and monocytes). Formal heterogeneity testing, such 
as HEIDI 27, as well as the investigation of novel methods such as that involving assessment 
of the meQTL over a locus, should be considered. It is worth noting that, as the breadth of 
coverage increases, the opportunity to directly assess pleiotropic effects within a locus will 
increase. That is, one can directly assess the association between a given genetic variant and 
those proteins that have been measured, as was the case for three of the five human PADI 
enzymes in Chapter 3.  
 
As mentioned above, GWA of the high-performance liquid-chromatography mass-
spectrometry features themselves is likely to be a profitable endeavour, as is a standard 
search of these data with additional allowable variable protein modifications (i.e. post-
translational modifications) and a non-synonymous variant aware search. Sample 
preparation for mass-spectrometry is designed to enrich the features present for peptide. 
This means that direct assessment of the genetic control of the features themselves enables 
the assessment of the genetic control of all the peptides detected in the sample, 
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irrespective of whether or not they have been identified. Formal identification of a feature 
can be undertaken retrospectively and may require an additional mass-spectrometry run 
with selection of the feature for fragmentation if it has not been fragmented in any of the 
samples or the library. If fragmentation has already been performed and the feature 
remains unidentified, then identification may be possible with the inclusion of additional 
modifications or protein sequences (e.g. non-synonymous mutations) in the database 
search; if identification remains elusive, then de novo sequencing may provide an 
identification. De novo sequencing of otherwise unidentified features, together with their 
genetic associations provides a means of identifying novel peptides, as well as the genetic 
loci that regulate their production. 
 
In addition to enabling the identification of outliers, between protein correlations, 
independent of the genetics, would allow for data-driven clustering of the proteins 
themselves, these data-driven groupings are likely to represent the true underlying 
biological pathways 4. Assessment of enrichment of such data-driven clusters with known 
biological pathways would provide a simple method of experimental, from myriad 
orthogonal sources, validation for such groupings. 
 
DNA CpG methylomics 
With respect to this body of work, there are many potentially fruitful future possibilities to 
pursue, including: 1) an assessment of commonality between those CpG sites under the 
control of SNPs associated with specific transcription factors, especially C2H2 and KRAB 
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containing transcription factors and, conversely, 2) is there any commonality in the 
molecules that mediate specific subsets of SNP:CpG pairs, for example, is there an 
enrichment of a specific protein family in those trans- acting meQTL for which the CpG is 
located in an enhancer element?, 3) is there an enrichment of a particular RNA species, i.e. 
the non-protein coding transcripts, identified as inter-chromosomal meQTLs?, and 4) in an 
analogous manner to inter-chromosomal meQTL, further investigation into the molecular 
mechanisms underpinning distantly- and locally- acting meQTL may be warranted. 
 
C2H2-ZF, including KRAB domain containing, transcription factors were enriched amongst 
sites associated with a locally- acting eQTL and inter-chromosomal meQTL when compared 
to all locally-acting eQTL in whole blood. One potential explanation for this is that the 
genetic variation affects the expression of the transcription factor locally, and the 
transcription factor then subsequently changes the transcriptional profile and methylation 
status at distant sites. To state this hypothesis explicitly, I suggest that the CpG location of 
the trans- acting meQTL indicate the genomic location(s) affected by the transcription factor 
encoded locally to the SNP, noting that this may be through direct or indirect mechanisms. 
Further support for this hypothesis could be obtained from existent eQTL data, that is, it 
could be assessed as to whether the trans- acting meQTL are also trans- acting eQTL for a 
transcript in the vicinity of the distant CpG. As noted previously, eQTL studies are often 
small and statistical power limited to detect trans- acting associations, however, this 
analysis would be more targeted than a simple genome-wide scan, at least in part mitigating 
this issue. Other potential confirmatory experiments could include targeted mutation of the 
	 129	
KRAB domain of a given transcription factor in a human cell line, followed by assessment of 
the methylation status at the relevant CpG sites (as indicated by the meQTL data). 
 
Final words 
This thesis has examined, in depth, the genetic effects controlling two intermediate traits – 
protein and DNA CpG methylation – at unprecedented scale in both arenas. I have taken 
these results and projected them onto, amongst other things, disease risk. I have, with 
moderate success, identified potential novel therapeutic targets and described previously 
unknown biology. I have demonstrated the benefit of using combined ‘-omics’ data, and 
hope to contribute a comprehensive assessment of the cellular proteome of peripheral 






Appendix 1: Materials relating to Chapter 2 
Supplementary Table 1. List of pQTLs (linkage disequilibrium clumped): indep_pqtl.tsv. 
List of lead-SNPs for each protein following linkage disequilibrium (LD) clumping, together 
with replication information. Biallelic variants within ±5Mb and r2 >0.2 to the lead variant 
(smallest p-value at the locus) were clumped together. European populations in 1,000 
Genomes92,93 were used as the LD reference.  
Columns are: 'hgnc_symbol': HUGO gene naming consortium symbol of the exposure 
(protein); 'snpid': 'chr'_'pos'; 'rsid': rsID; 'chr': chromosome (GRCh37) of the SNP; 'pos': 
position (GRCh37) of the SNP; 'a1': effect allele; 'a0': other allele; 'n_pri': number of 
individuals in the primary cohort (CROATIA-Vis); 'freq1_pri': frequency of the effect allele is 
the primary cohort (CROATIA-Vis); 'beta1_pri': beta estimate of the effect allele in the 
primary cohort (CROATIA-Vis); 'se_pri': standard error of 'beta1_pri' in the primary cohort 
(CROATIA-Vis); 'p_pri': p-value of 'beta1_pri' and 'se_pri'; 'info_pri': SNPTEST (v2) info of 
the imputation in the primary cohort (CROATIA-Vis); 'r2_pri': coefficient of determination 
of the regression in the primary cohort (CROATIA-Vis); 'n_sec': as for the primary cohort 
(CROATIA-Vis) but in the secondary cohort (ORCADES); 'freq1_sec': as for the primary 
cohort (CROATIA-Vis) but in the secondary cohort (ORCADES); 'beta1_sec': as for the 
primary cohort (CROATIA-Vis) but in the secondary cohort (ORCADES); 'se_sec': as for the 
primary cohort (CROATIA-Vis) but in the secondary cohort (ORCADES); 'p_sec': as for the 
primary cohort (CROATIA-Vis) but in the secondary cohort (ORCADES); 'info_sec': as for the 
primary cohort (CROATIA-Vis) but in the secondary cohort (ORCADES); 'r2_sec': as for the 
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primary cohort (CROATIA-Vis) but in the secondary cohort (ORCADES); 'uniprot_swissprot': 
UniProtID of the exposure (protein), see http://www.uniprot.org/; 'ensembl_gene_id': 
Ensembl gene ID (GRCh37; see http://grch37.ensembl.org/index.html) of the gene-of-
origin of the protein; 'chromosome_name': chromosome (GRCh37) of the gene of the 
protein, as per Ensembl GRCh37; 'start_position': start position (GRCh37) of the gene of 
the protein, as per Ensembl GRCh37; 'end_position': end position (GRCh37) of the gene of 
the protein, as per Ensembl GRCh37; 'description': HUGO gene naming consortium 
description of the exposure (protein); 'replicated_pqtl': is the lead-SNP of the cluster (as 
identified in the primary cohort) replicated in the secondary cohort (Bonferroni correction 
for multiple testing. TRUE if it is; FALSE if not); 'within_gene_plus_flank_tol': is the SNP 
within the gene-of-origin of the protein +/- 150kb (TRUE is it is; FALSE if not). 
 
Supplementary Table 2. Comparison of the lead-SNPs identified here and eQTL: ‘pQTL_eQTL.tsv’. 
eQTL data derived from ‘Whole blood’ from GTEx13 (v7). Bonferroni correction 0.05/54. 
Columns are ‘hgnc_symbol’: the HGNC symbol corresponding to the UniProtID; ‘rsid’: rsID of 
the SNP; ‘chr’: chromosome of the SNP, GRCh37; ‘pos’: position of the SNP, GRCh37; ‘a1’: 
the effect allele; ‘a0’: the other allele; ‘uniprot’: UniProtID of the protein; ‘n_protein_pri’: 
number of individuals in the primary protein cohort (CROATIA-Vis); ‘freq1_protein_pri’: 
frequency of the effect allele in the primary protein cohort (CROATIA-Vis); 
‘beta1_protein_pri’: effect-size estimate in the primary protein cohort (CROATIA-Vis); 
‘se_protein_pri’: standard error of ‘beta1_protein_pri’; ‘p_protein_pri’: p-value of 
‘beta1_protein_pri’ and ‘se_protein_pri’; ‘info_protein_pri’: SNPTEST (v2) imputation info 
score in the primary protein cohort (CROATIA-Vis); ‘n_protein_sec’: as for the primary 
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cohort (CROATIA-Vis) but in the secondary cohort (ORCADES); ‘freq1_protein_sec’: as for 
the primary cohort (CROATIA-Vis) but in the secondary cohort (ORCADES); 
‘beta1_protein_sec’: as for the primary cohort (CROATIA-Vis) but in the secondary cohort 
(ORCADES); ‘se_protein_sec’: as for the primary cohort (CROATIA-Vis) but in the secondary 
cohort (ORCADES); ‘p_protein_sec’: as for the primary cohort (CROATIA-Vis) but in the 
secondary cohort (ORCADES); ‘info_protein_sec’: as for the primary cohort (CROATIA-Vis) 
but in the secondary cohort (ORCADES); ‘ensembl_gene_id’: Ensembl gene ID corresponding 
to the protein; ‘pval_nominal_gtex’: nominal p-value in GTEx (v7) whole blood; ‘slope_gtex’: 
effect-size estimate in GTEx (v7) whole blood; ‘slope_se_gtex’: standard error of 
‘slope_gtex’ in GTEx (v7) whole blood; ‘pval_nominal_threshold_gtex’: nominal p-value 
threshold for calling a variant-gene pair significant for the gene in GTEx (v7) whole blood; 
‘min_pval_nominal_gtex’: smallest nominal p-value for the gene in GTEx (v7) whole blood; 
‘pval_beta’: beta-approximated permutation p-value for the gene in GTEx (v7) whole blood. 
 
Supplementary Table 3. Comparison of the lead-SNPs identified here and those identified using an orthogonal, aptamer-
based assay: ‘ld_list_olink_sun_with_ld.tsv’. 
Aptamer-based assay results are those of Sun et al.14. 
Columns are ‘hgnc_symbol’: the HGNC symbol corresponding to the UniProtID; ‘exposure’: 
the UniProtID of the protein; ‘rsid_olink’: the rsID of the lead-SNP from this study; 
‘chr_olink’: the chromosome, GRCh37, of the lead-SNP from this study; ‘pos_olink’: the 
position, GRCh37, of the lead-SNP from this study; ‘a1_olink’: allele 1 of the lead-SNP from 
this study; ‘a0_olink’: allele 0 of the lead-SNP from this study; ‘rsid_sun’: the rsID of the 
lead-SNP from Sun et al.; ‘chr_sun’: the chromosome, GRCh37, of the lead-SNP from Sun et 
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al.; ‘pos_sun’: the position, GRCh37, of the lead-SNP from Sun et al.; ‘a1_sun’: allele 1 of the 
lead-SNP from Sun et al.; ‘a0_sun’: allele 0 of the lead-SNP from Sun et al.; ‘ld_r2’: the 
linkage disequilibrium (r2) of the two SNPs, as measured in the European individuals from 
1,000 Genomes (Methods). 
 
Supplementary Table 4. Additional studies identified using Phenoscanner: additional_studies.tsv. 
Table of the additional studies (and outcome traits) identified through Phenoscanner67,68. 
Note that ‘Coronary artery disease’ was included from van der Harst et al.61 both with and 
without the inclusion of data from UK Biobank.  
Columns are ‘Outcome’: trait under study; ‘PMID’: Pubmed ID of the study; ‘First author’: 
First author the publication; ‘Year’: year of publication of the study; ‘Paper title’: title of the 
study. 
 
Supplementary Table 5. Mendelian Randomisation results from GeneAtlas: df_ukbb_heidi.tsv. 
Table of the all significant (FDR <0.05) Mendelian Randomisation (MR) results using data 
from GeneAtlas29 together with their HEIDI27 test statistic results. pQTL for both cohorts 
are included, however, in order to avoid a ‘winner’s curse’, MR and HEIDI were conducted 
using data from the secondary protein cohort (ORCADES). 
Columns are 'hgnc_symbol': HUGO Gene Nomenclature Committee symbol of the 
exposure protein; 'outcome_description': description of the UK biobank outcome from 
GeneAtlas; 'rsid': rsID; 'snpid': 'chr'_'pos'; 'chr': chromosome (GRCh37); 'pos': position 
(GRCh37); 'a1': effect allele; 'a0': other allele; 'exposure': UniProtID of the protein; 
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'ensembl_gene_id': Ensembl (GRCh37) gene ID of the exposure protein; 'n_exposure_pri': 
number of individuals in the primary protein cohort (CROATIA-Vis); 'freq1_exposure_pri': 
frequency of the effect allele in the primary protein cohort (CROATIA-Vis); 
'beta1_exposure_pri': regression coefficient (per additional effect allele) in the primary 
protein cohort (CROATIA-Vis); 'se_exposure_pri': standard error of ‘beta1_exposure_pri’; 
'p_exposure_pri': p-value of ‘beta1_exposure_pri’ and ‘se_exposure_pri’; 
'info_exposure_pri': SNPTEST (v2) imputation info score in the primary protein cohort 
(CROATIA-Vis); 'n_exposure_sec': as for the primary cohort (CROATIA-Vis) but in the 
secondary cohort (ORCADES); 'freq1_exposure_sec': as for the primary cohort (CROATIA-
Vis) but in the secondary cohort (ORCADES); 'beta1_exposure_sec': as for the primary 
cohort (CROATIA-Vis) but in the secondary cohort (ORCADES); 'se_exposure_sec': as for 
the primary cohort (CROATIA-Vis) but in the secondary cohort (ORCADES); 
'p_exposure_sec': as for the primary cohort (CROATIA-Vis) but in the secondary cohort 
(ORCADES); 'info_exposure_sec': as for the primary cohort (CROATIA-Vis) but in the 
secondary cohort (ORCADES); 'outcome': outcome code of the UK biobank outcome from 
GeneAtlas; 'beta1_outcome': beta of the effect allele on the outcome in GeneAtlas; 
'se_outcome': standard error of ‘beta1_outcome’; 'p_outcome': p-value corresponding to 
‘beta1_outcome’ and ‘se_outcome’; 'info_outcome': imputation info score in UK Biobank; 
'freq1_outcome': frequency of the effect allele in UK Biobank; 'beta_mr_delta_sec': beta 
value using the delta MR method (using up to second order partial derivatives; See the 
appendix of Lynch and Walsh for further information) using estimates from the secondary 
cohort; 'se_mr_delta_sec': standard error of 'beta_mr_delta_sec' using the delta MR 
method (using up to first order partial derivatives; See the appendix of Lynch and Walsh 
for further information) using estimates from the secondary cohort; 'p_mr_delta_sec': p-
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value corresponding to 'beta_mr_delta_sec' and 'se_mr_delta_sec'; 
'fdr_sig_mr_delta_sec': significance of 'p_mr_delta_sec' at a False Discovery Rate (FDR) of 
<5%. True / False; 'p_HEIDI': p-value of the HEIDI statistic; 'nsnp_HEIDI': the number of 
SNPs used in the calculation of the HEIDI statistic. 
 
Supplementary Table 6. Mendelian Randomisation results from studies identified using Phenoscanner: 
df_phenoscanner.tsv. 
Table of all Mendelian Randomisation results using data acquired through 
Phenoscanner67,68. pQTL for both cohorts are included, however, in order to avoid a 
‘winner’s curse’, MR was conducted using data from the secondary protein cohort.  
Columns are 'hgnc_symbol': HUGO Gene Nomenclature Committee symbol of the exposure 
protein; 'trait': outcome trait description; 'snp': chr'chr':'pos'; 'rsid': rsID; 'chr': 
chromosome (GRCh37); 'pos': position (GRCh37); 'a1': effect allele; 'a0': other allele; 
'exposure': UniProtID of the protein; 'n_exposure_pri': number of individuals in the primary 
protein cohort (CROATIA-Vis); 'freq1_exposure_pri': frequency of the effect allele in the 
primary protein cohort (CROATIA-Vis); 'beta1_exposure_pri': regression coefficient (per 
additional effect allele) in the primary protein cohort (CROATIA-Vis); 'se_exposure_pri': 
standard error of 'beta1_exposure_pri'; 'p_exposure_pri': p-value of 'beta1_exposure_pri' 
and 'se_exposure_pri'; 'info_exposure_pri': SNPTEST (v2) imputation info score in the 
primary protein cohort; 'n_exposure_sec': as for the primary cohort (CROATIA-Vis) but in 
the secondary cohort (ORCADES); 'freq1_exposure_sec': as for the primary cohort 
(CROATIA-Vis) but in the secondary cohort (ORCADES); 'beta1_exposure_sec': as for the 
primary cohort (CROATIA-Vis) but in the secondary cohort (ORCADES); 'se_exposure_sec': 
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as for the primary cohort (CROATIA-Vis) but in the secondary cohort (ORCADES); 
'p_exposure_sec': as for the primary cohort (CROATIA-Vis) but in the secondary cohort 
(ORCADES); 'info_exposure_sec': as for the primary cohort (CROATIA-Vis) but in the 
secondary cohort (ORCADES); 'ensembl_gene_id': Ensembl (GRCh37) gene ID of the 
exposure protein; 'study': name of the consortium/lead author of the outcome study; 
'pmid': PubMed ID of the outcome study; 'ancestry': ancestry of the population within 
which the outcome was measured; 'year': the year the outcome study was published; 
'beta1_outcome': regression coefficient (per additional effect allele) in the outcome study; 
'se_outcome': standard error of 'beta1_outcome'; 'p_outcome': p-value of 
'beta1_outcome' and 'se_outcome'; 'n_outcome': number of individuals in the outcome 
study; 'n_cases_outcome': number of cases in the outcome study; 'n_controls_outcome': 
number of controls in the outcome study; 'n_studies_meta_outcome': if a meta-analysis, 
number of studies included; 'units_outcome': units of analysis in the outcome study (IVNT 
stands for inverse normal rank transformed phenotype); 'dataset': Phenoscanner dataset 
ID; 'beta1_outcome_flipped': has the sign of 'beta1_outcome' been inverted from that 
provided by Phenoscanner due to calling of the effect vs. non-effect allele? True / False; 
'beta_mr_delta_sec': beta value using the delta MR method (using up to second order 
partial derivatives; See the appendix of Lynch and Walsh for further information) using 
estimates from the secondary cohort; 'se_mr_delta_sec': standard error of 
‘beta_mr_delta_sec’ using the delta MR method (using up to first order partial derivatives; 
See the appendix of Lynch and Walsh for further information) using estimates from the 
secondary cohort; 'p_mr_delta_sec': p-value corresponding to 'beta_mr_delta_sec' and 
'se_mr_delta_sec'; 'fdr_sig_mr_delta_sec': significance of 'p_mr_delta_sec' at a False 
Discovery Rate (FDR) of <5% (True / False). 
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Supplementary Table 7. ChEMBL results: chembl_matches.tsv. 
Compounds targeting the mediators listed in Supplementary Table 5. Columns are ‘uniprot’: 
UniProtID; ‘gene_symbol’: Gene Symbol; ‘target_chembl_id’: CHEMBL ID for this protein ; 
‘compound_id’: CHEMBL compound ID; ‘max_phase’: CHEMBL-reported maximum phase of 
drug development for this compound; ‘drug_synonyms’: drug names; ‘indication_class’:  
CHEMBL-reported indication for this compound. 
 
Supplementary Table 8. Key of Figure 2a: df_phenoscanner_outcomes.tsv. 
Key for the abbreviations used in Figure 2a. 
Columns are ‘Abbreviation’ and ‘Outcome Description’. 
 
Supplementary Table 9: Key of Figure 2b: df_ukbb_outcomes.tsv. 
Key for the abbreviations used in Figure 2b. 
Columns are ‘Abbreviation’ and ‘Outcome Description’. 
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Appendix 2: Materials relating to Chapter 3 
Protocol: preparation of cell lysate. 
1. Collect samples from LN2, allow to thaw on ice. 
2. Label 15 ml falcon tubes. 
3. Prep Cat 2 room 
a. Get from outside: Ice, PBS, labelled 0.5ml centrifuge tubes, lysis buffer, 
beaker for tips in hood, boxes of filter tips: 1 x 200ul, 2 x 1000ul, 10ml 
stripettes, 15ml falcon tubes, dry ice. 
b. Prepare hood. 
4. Add 9ml Phosphate Buffered Saline (PBS) to each 15ml falcon tube. 
5. Ensure cells adequately suspended. 
6. Transfer cells to labelled 15ml falcon. 
7. Repeat steps 5-6 for each sample in batch. 
8. Wash cells x2 
a. Spin sample 400g for 10min at 4degC   
i. First Batch:  1. A [__] B [__]  2. A [__] B [__] 
ii. Second Batch:  1. A [__] B [__]  2. A [__] B [__] 
b. Remove supernatant. 
c. Resuspend pellet in 10ml PBS. 
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9. Spin sample 400g for 10min at 4degC. 
a. First Batch:  3. A [__] B [__] 
b. Second Batch:  3. A [__] B [__] 
10. Remove supernatant. 
11. Resuspend pellet in 40ul of ‘lysis buffer’ (6M Guanidine HCl + 100mM Tris pH8.5). 
12. Transfer to 0.5ml centrifuge tubes. 
13. Place the samples on dry ice. 
14. Prepare to exit the Cat 2 room. 
15. Thaw samples. 
16. Sonicate samples for 10sec 5um with Soniprep 150. 
17. Place samples back on dry ice. 
 
Protocol: Digest, day 1 
1. Add 18ul H2O to wells A1 : D12 of ‘protein assay plate’ (‘A’). 
2. Thaw samples. 
3. Spin samples to bottom of 0.5ml centrifuge tubes. 
4. From the 0.5ml centrifuge tubes put 2ul of sample onto ‘protein assay plate’ (‘A’) 
and return 0.5ml centrifuge tubes to dry ice. 
5. Perform Protein Assay. 
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a. Per batch: Make reagent A and B mix (20ml reagent A, 400ul reagent B). 
b. Add 180ul of reagent A and B mix to all wells of ‘protein assay plate’ (‘A). 
c. Incubate for 30mins. 
6. Calculate the volume of sample and the volume of lysis buffer (6M Guanidine HCl + 
100mM Tris pH8.5) required to standardise amount of protein per well to 15ug 
(using spreadsheet template to create a manifest). 
7. Thaw samples on ice. 
8. BETWEEN BATCH REPEATS 
a. Transfer specified volume, as directed by the manifest, of lysis buffer onto 
the ‘digest plate’ (‘D’) of subsequent digests. 
b. Transfer specified volume, as directed by the manifest, of sample onto the 
‘digest plate’ (‘D’) of subsequent digests. 
c. Place any digest plates that are not for immediate processing in the freezer (-
20degC). 
9. WITHIN BATCH REPEAT: Transfer the specified volume, as per the manifest, of lysis 
buffer of the sample to be repeated into D10 of the ‘digest plate’ (‘D’). 
10. STANDARD SAMPLE: Transfer specified volume, as per the manifest, of lysis buffer 
onto the ‘digest plate’ (‘D’). 
11. WITHIN BATCH REPEAT: Transfer specified volume, as per the manifest, of the 
sample to be repeated into D10 of the ‘digest plate’ (‘D’) 
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12. STANDARD SAMPLE: Transfer specified volume, as per the manifest, of sample onto 
the ‘digest plate’ (‘D’). 
13. Transfer the remaining sample into to the ‘lysate storage plate’ (‘L’) and place in the 
freezer (-20degC). 
14. Add 1ul of 100mM TCEP to each well of ‘digest plate’ (‘D’). 
15. Add 1ul of 200mM CAA to each well of ‘digest plate’ (‘D’). 
16. Place lid on ‘digest plate’ (‘D’). 
17. Boil ‘digest plate’ (‘D’) (95degC for 5min). 
18. Remove from block and allow to cool for 5 min. 
19. Spin down condensate. 
20. Add 20ul LysC working reagent to each well. 
a. LysC working reagent, per batch: resuspend 1 ampule (20ug) LysC in + 1333ul 
pre-prepared LysC buffer (100mM Tris pH 8.5). 
21. Check pH [__] 
a. Ensure pH8 to 8.5. 
22. Incubate at 37degC overnight (16 hours). 
 
Protocol: Digest, day 2 
1. Spin down condensate. 
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2. Make up trypsin working reagent. 
a. Per batch: 4ml Trypsin buffer (50mM Tris pH8.5) + 7.5ul Trypsin stock (1 ug/ul 
Trypsin in 0.1% TFA). 
3. Add 80ul of trypsin working reagent to each well of ‘digest plate’ (‘D’). 
4. Check pH [__] 
a. Ensure pH 8 to 8.5. 
5. Incubate for 4 hours at 37degC. 
6. Prepare C18 stage tips (with two pieces of C18 per tip). 
7. Spin down condensate. 
8. Add 15ul of methanol to each tip. 
9. Spin tips: 300g, 2 min, 22degC. 
10. Add 50ul of 0.1% TFA to each tip. 
11. Spin tips: 300-500g, 5 min, 22degC. 
12. Add 16ul of 10% TFA to each well of ‘digest plate’ (‘D’). 
13. Check pH [__] 
a. Ensure <=3. 
14. Transfer 120ul of samples from ‘digest plate’ (‘D’) to stage tips. 
15. Spin tips: 500-900g, 5 min, 22degC. 
a. Repeat as necessary if liquid not fully through tip. 
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16. Add 50ul 0.1% TFA to tips. 
17. Spin tips: 500-900g, 5min, 22degC. 
a. Repeat as necessary if liquid not fully through tip. 
18. Place stage tips into adapter above ‘Elution plate’ (‘E’). 
19. Add 40ul of 80% acetonitrile (ACN) + 0.1% TFA to tips. 
20. Spin tips: 200-500g, 5min, 22degC. 
a. Repeat as necessary if liquid not fully through tip. 
21. Put lid on plate for transfer to centrifuge. 
22. Dry ‘Elution plate’ (‘E’) in vacuum centrifuge: 20min, 30degC, high-volatile (without 
lid). 
a. Repeat if not fully dry at the end of centrifugation. 
23. Resuspend samples in 14ul of MS grade water. 
a. Wait 30min for adequate resuspension. 
24. Transfer 5ul of each well of ‘Elution plate’ (‘E’) to ‘Peptide Assay plate’ (‘A’). 
25. Add 1ul of 1% TFA to each well of ‘Elution plate’ (‘E’). 
26. Check pH ~3. 
27. Store peptide assay plate for later processing. 
28. Thaw 20ul aliquot of pooled standard. 
29. Spin pooled standard to bottom of tube. 
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30. Add pooled standard to D12 of elution plate. 
31. Spin samples to bottom of ‘elution plate’. 
32. Place ‘elution plate’ into freezer (-20degC) pending processing. 
 
Supplementary Table 10: comparison of PBMC pQTL to whole blood eQTL 
‘a32_gtex_v6p_whole_blood_matched_harmonised.tsv’ 
Comparison of the significant (FDR <0.05) locally- acting PBMC pQTL with the locally- acting 
whole blood eQTL from GTEx (v6p) 13. 
 
Column Description 
rsid rsID of the SNP 
chr Chromosome (GRCh37) 
pos Position (GRCh37) 
a1_prot Effect allele in the protein model 
a0_prot Other allele in the protein model 
freq1_prot Allele frequency of the effect allele 
n_missing_geno Number of individuals with missing data for the SNP in 
the protein study 
n_missing_prot Number of proteins with missing data for the protein 
study (of 251) 
uniprot_swissprot UniProtKB / Swiss-Prot ID 
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ENSG_ID Ensembl gene ID 
gene_name Ensembl gene name 
gene_start Start position of the gene (Ensembl GRCh37) 
gene_end End position of the gene (Ensembl GRCh37) 
tss_distance Distance to transcription start site (as per GTEx v6p) 
beta1_prot Beta effect estimate (per 'a1_prot') on protein 
p_prot p-value associated with 'beta1_prot' 
a1_gtex Effect allele in GTEx (v6p) 
a0_gtex Other allele in GTEx (v6p) 
beta1_gtex Beta effect estimate (per 'a1_gtex') on expression in GTEx 
(v6p) 
p_nominal_gtex Nominal p-value of 'beta1_gtex' in GTEx (v6p) 
p_nominal_thresh_gtex Nominal p-value threshold for 'p_nominal_gtex' in GTEx 
(v6p) 




Appendix 3: Materials relating to Chapter 4 
Supplementary Table 11: Regression results 
Significant results from the regression on dominance and absolute additive effect-sizes 
(Equation 4.4 and Equation 4.5) in the primary set. All significant (Bonferroni correction) 
results from the primary set presented. The results of these annotations, when analysed in 
the secondary (replication) set are also included. Bonferroni correction for multiple testing 
(primary set): CODEX p-value <0.05/96; Encode Segmentation 0.05/14; Cistrome Epigenome 
0.05/21. 
 
Bonferroni correction for multiple testing (secondary set), dependent on the number of 
significant results in the primary set. Dominance: CODEX p-value <0.05/36; Encode 
Segmentation 0.05/4; Cistrome Epigenome 0.05/9. Additive: CODEX p-value <0.05/1; 
Encode Segmentation 0.05/1; Cistrome Epigenome 0.05/1. 
 
† indicates successful replication. 
 
All significant loci are with reference to the CpG location. None of the annotations were 
significant with respect to the SNP location. 
 
Columns headings. ‘Dependent variable’: which model is the result in reference to? ‘Dom’ is 
Equation 4.4, ‘Add’ is Equation 4.5; ‘Collection’, which collection is the annotation from?; 
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‘Set’: the set (primary n = 4,101, secondary n=1,000) the result is from; ‘Antibody’: the 
antibody used for the Chip-Seq experiment; ‘Beta’: the effect-size estimate of the 
annotation on the dependent variable (as part of the model in Equation 4.4 / Equation 4.5); 





Collection Set Antibody Beta se p-value 
Add CODEX Primary KDM5B 0.05 0.01 6.61E-05 
Add CODEX Secondary KDM5B 0.02 0.02 1.38E-01 
Dom CODEX Primary RUNX3 0.04 0.01 2.50E-11 
Dom CODEX Secondary RUNX3 0.05 0.01 4.30E-05† 
Dom CODEX Primary RUNX1T1 0.03 0.01 2.76E-04 
Dom CODEX Secondary RUNX1T1 0.02 0.02 3.00E-01 
Dom CODEX Primary TCF12 0.04 0.01 4.44E-10 
Dom CODEX Secondary TCF12 0.05 0.01 2.87E-04† 
Dom CODEX Primary TCF3 0.03 0.01 1.79E-04 
Dom CODEX Secondary TCF3 0.07 0.02 2.26E-04† 
Dom CODEX Primary LMO2 0.04 0.01 5.35E-05 
Dom CODEX Secondary LMO2 0.04 0.02 6.57E-02 
Dom CODEX Primary BCL6 0.04 0.01 3.66E-08 
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Dom CODEX Secondary BCL6 0.04 0.02 1.08E-02 
Dom CODEX Primary ERG 0.05 0.01 2.46E-12 
Dom CODEX Secondary ERG 0.06 0.01 2.63E-05† 
Dom CODEX Primary FLI1 0.03 0.01 4.20E-04 
Dom CODEX Secondary FLI1 0.04 0.02 1.57E-02 
Dom CODEX Primary TAL1 0.03 0.01 1.08E-05 
Dom CODEX Secondary TAL1 0.04 0.02 1.21E-02 
Dom CODEX Primary GATA2 0.04 0.01 4.47E-06 
Dom CODEX Secondary GATA2 0.03 0.02 9.19E-02 
Dom CODEX Primary RUNX1 0.04 0.01 1.19E-12 
Dom CODEX Secondary RUNX1 0.05 0.01 2.22E-05† 
Dom CODEX Primary CBFB 0.03 0.01 6.88E-07 
Dom CODEX Secondary CBFB 0.05 0.01 1.07E-04† 
Dom CODEX Primary MYH11 0.04 0.01 4.29E-09 
Dom CODEX Secondary MYH11 0.05 0.01 2.60E-04† 
Dom CODEX Primary MED21 0.04 0.01 5.56E-08 
Dom CODEX Secondary MED21 0.06 0.02 9.88E-05† 
Dom CODEX Primary TBP 0.03 0.01 1.89E-05 
Dom CODEX Secondary TBP 0.04 0.02 1.96E-02 
Dom CODEX Primary ELF1 0.03 0.01 3.24E-05 
Dom CODEX Secondary ELF1 0.03 0.02 5.35E-02 
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Dom CODEX Primary SPI1 0.03 0.01 1.06E-04 
Dom CODEX Secondary SPI1 0.02 0.01 1.60E-01 
Dom CODEX Primary EP300 0.04 0.01 2.47E-07 
Dom CODEX Secondary EP300 0.05 0.01 1.07E-03† 
Dom CODEX Primary HDAC1 0.03 0.01 4.59E-06 
Dom CODEX Secondary HDAC1 0.05 0.01 1.36E-03† 
Dom CODEX Primary FOXA2 0.03 0.01 5.79E-07 
Dom CODEX Secondary FOXA2 0.03 0.01 1.81E-02 
Dom CODEX Primary POLR2A 0.04 0.01 2.77E-13 
Dom CODEX Secondary POLR2A 0.06 0.01 3.40E-06† 
Dom CODEX Primary ETS1 0.04 0.01 4.94E-10 
Dom CODEX Secondary ETS1 0.05 0.01 1.75E-04† 
Dom CODEX Primary NOTCH1 0.04 0.01 3.87E-09 
Dom CODEX Secondary NOTCH1 0.05 0.01 2.08E-04† 
Dom CODEX Primary RBPJ 0.04 0.01 7.33E-06 
Dom CODEX Secondary RBPJ 0.05 0.02 2.87E-03 
Dom CODEX Primary BRD4 0.03 0.01 1.39E-04 
Dom CODEX Secondary BRD4 0.04 0.02 1.84E-02 
Dom CODEX Primary MED1 0.03 0.01 1.92E-04 
Dom CODEX Secondary MED1 0.03 0.01 1.71E-02 
Dom CODEX Primary P300 0.03 0.01 5.02E-05 
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Dom CODEX Secondary P300 0.04 0.02 1.72E-02 
Dom CODEX Primary GATA1 0.03 0.01 4.51E-05 
Dom CODEX Secondary GATA1 0.03 0.02 3.93E-02 
Dom CODEX Primary CDK7 0.04 0.01 1.54E-06 
Dom CODEX Secondary CDK7 0.05 0.02 4.44E-04† 
Dom CODEX Primary MYB 0.04 0.01 3.35E-09 
Dom CODEX Secondary MYB 0.05 0.01 2.61E-04† 
Dom CODEX Primary PHF8 0.04 0.01 1.71E-11 
Dom CODEX Secondary PHF8 0.05 0.01 4.50E-04† 
Dom CODEX Primary KDM5B 0.03 0.01 8.14E-06 
Dom CODEX Secondary KDM5B 0.04 0.01 3.34E-03 
Dom CODEX Primary RBBP5 0.04 0.01 1.46E-08 
Dom CODEX Secondary RBBP5 0.04 0.01 6.55E-03 
Dom CODEX Primary SAP30 0.04 0.01 3.18E-07 
Dom CODEX Secondary SAP30 0.03 0.02 3.55E-02 
Dom CODEX Primary KDM4A 0.04 0.01 1.34E-08 
Dom CODEX Secondary KDM4A 0.04 0.01 4.80E-03 
Dom CODEX Primary BCOR 0.04 0.01 5.69E-08 
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